Clinical trial register · France

Clinical Trials in Montpellier, 2026

Every study on the ClinicalTrials.gov registry that lists a site in France and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 9697 matching records held by the registry are in this view. Synced 26 Oct 2026, 03:20 UTC

9697

Studies in scope

all four open statuses

6025

Recruiting now

open to new participants

1033

Lead sponsors

across recruiting studies

Top sites

Paris 2821 Lyon 1392 Bordeaux 1389 Marseille 1285 Lille 1282

Trials with a site in Montpellier

Status

Study

Lead sponsor

Phase

Enrol

Sites in France

Start

Not yet open

Leukocyte- and Platelet-Rich Fibrin in the Surgical Treatment of Medication-related Osteonecrosis of the Jaw

NCT06419010Osteonecrosis of the Jaw

University Hospital, Toulouse

Not applicable

150

Bordeaux, Limoges, Montpellier, Paris, Toulouse

2024-05

Active, closed

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

NCT06383390Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)

DrugRetatrutide

Eli Lilly and Company

Phase 3

10,000

Bois-Guillaume, Bordeaux, Clermont-Ferrand, Corbeil-Essonnes, La Tronche, Le Coudray, Montpellier, Nantes

2024-04-30

Recruiting

Prevalence of Psychiatric Disorders During Pregnancy at 2nd Trimester Ultrasound: a Feasibility Study in the General Population

NCT06297252Pregnancy

University Hospital, Montpellier

Not applicable

140

Béziers, Montpellier

2024-04-25

Recruiting

Glial Fibrillary Acidic Protein (GFAP) and Ubiquitin Carboxy-terminal Hydrolase L1 (UCH-L1) to Exclude Lesions Linked to Significant Traumatic Brain Injuries

NCT05885529Traumatic Brain Injury

Centre Hospitalier Princesse Grace

Observational

1,500

Angers, Clermont-Ferrand, Dijon, Grenoble, Lyon, Montpellier, Nantes, Nice

2024-04-19

Active, closed

A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.

NCT06372145Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis

DrugTeriflunomide

Sanofi

Phase 3

2,500

Besançon, Bron, Clermont-Ferrand, Gonesse, Lille, Montpellier, Nancy, Nantes

2024-04-16

Recruiting

Risk Prevention Program and Therapeutic Patient Education Program of Patients With Uncontrolled Epilepsy

NCT06202196Epilepsy

University Hospital, Montpellier

Not applicable

Montpellier, Toulouse

2024-04-16

Recruiting

French Assessment of MRD by Liquid Biopsies in Colorectal With Liver Metastasis Patients (FRENCH.MRD.CRLM)

NCT06287723Colorectal Cancer, Liver Metastases, Stage IV Colorectal Cancer, Minimal Residual Disease

DrugBlood sample/Liquid biopsy

University Hospital, Montpellier

Observational

Montpellier

2024-04-15

Recruiting

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

NCT06312176Breast Neoplasms

DrugsLiposomal doxorubicin·Abraxane·Xeloda·Sacituzumab tirumotecan

Merck Sharp & Dohme LLC

Phase 3

1,200

Lyon, Caen, Montpellier, Nantes, Poitiers, Paris

2024-04-14

Recruiting

French Assessment of MRD by Liquid Biopsies in Stage III CRC Patients (FRENCH.MRD.CRC)

NCT06287814Colorectal Cancer, Stage III Colon Cancer, Minimal Residual Disease, Liquid Biopsy

University Hospital, Montpellier

Observational

Montpellier

2024-04-11

Recruiting

A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

NCT06330064Recurrent or Metastatic Solid Tumors

DrugIfinatamab Deruxtecan

Daiichi Sankyo

Phase 1/2

680

Dijon, Bordeaux, Montpellier, Rennes, Saint-Herblain, Paris, Lyon, Villejuif

2024-04-10

Recruiting

Cannabidiol as an add-on Treatment During Inpatient Alcohol Cessation : CBD-OH

NCT05860699Severe Alcohol Use Disorder (DSM 5)

Assistance Publique - Hôpitaux de Paris

Phase 2

210

Créteil, Clamart, Clermont-Ferrand, Colombes, Bobigny, Paris, Sevran, Montpellier

2024-04-08

Active, closed

A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis

NCT06329401Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Pulmonary Fibrosis Secondary to Systemic Sclerosis, Pulmonary Fibrosis, Interstitial Lung Disease

DrugPirfenidone

Avalyn Pharma Inc.

Phase 2

398

Rennes, Tours, Metz, Lyon, Montpellier, Angers, Le Kremlin-Bicêtre, Paris

2024-04-03

Recruiting

Validation of a Magnetic Sensor in Arterial Flow Recording, Compared With the Reference Method, at Various Peripheral Arterial Sites

NCT06274697Lower Extremity Artery Disease

University Hospital, Montpellier

Not applicable

Montpellier

2024-04-02

Recruiting

A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors

NCT06265727Solid Tumor, Adult

DrugsCRB-701·Anti-PD-1

Corbus Pharmaceuticals Inc.

Phase 1/2

348

Montpellier, Poitiers, Saint-Herblain, Villejuif

2024-04-01

Recruiting

Efficacy Investigation of the Medical Device Apneal® on Smartphone for Sleep Apnea-Hypopnea Syndrome Diagnosis

NCT06578390Sleep Apnea Syndromes

Mitral

Not applicable

500

Aix-en-Provence, Antony, Bordeaux, Montpellier, Mulhouse, Paris, Reims, Roanne

2024-03-26

Recruiting

Pharmacokinetic Modeling of Methadone

NCT05490732Toxicomania

DrugBlood sampling

University Hospital, Montpellier

Not applicable

100

Montpellier

2024-03-23

Recruiting

Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary Sarcoidosis

NCT06205121Pulmonary Sarcoidosis

Molecure S.A.

Phase 2

Bobigny, Montpellier, Paris

2024-03-21

Recruiting

Comparison of Two Strategies of One-lung Ventilation in Patients Undergoing Carcinological Lung Resection Surgery.

NCT05525312Lung Diseases

University Hospital, Montpellier

Not applicable

120

Montpellier

2024-03-20

Recruiting

Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study

NCT05904119First Progression of Glioblastoma

DrugLomustine

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3

411

Amiens, Clermont-Ferrand, Lille, Lyon, Montpellier, Nice, Paris, Saint-Herblain

2024-03-15

Active, closed

A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

NCT06132893Focal Epilepsy

DrugOpakalim

Biohaven Therapeutics Ltd.

Phase 2/3

390

Strasbourg, Dijon, Toulouse, Montpellier, Tours, Nancy, Lille, Lyon

2024-03-14

Recruiting

Analysis of the Prevalence of Sensitization to Plants Containing Gibberellins Using Realistic Skin Prick Tests

NCT06183398Food Allergy

University Hospital, Montpellier

Not applicable

2,000

Montpellier

2024-03-14

Recruiting

Daridorexant to Treat Insomnia in Patients With Mild Cognitive Impairment and Mild to Moderate Alzheimer Disease

NCT05924425Alzheimer Disease, Insomnia Disorder, Sleep

DrugDaridorexant

University Hospital, Montpellier

Phase 4

Montpellier

2024-03-13

Recruiting

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

NCT06318169Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis

DrugPegozafermin

Hoffmann-La Roche

Phase 3

1,350

Amiens, Angers, Bordeaux, Clichy, Lille, Limoges, Lyon, Montpellier

2024-03-13

Recruiting

Analgesic Effectiveness of Capsaicin 8% Cutaneous Patch in Children

NCT05997979Neuropathic Pain, Chronic Pain

DrugCapsaicin

University Hospital, Brest

Phase 3

Amiens, Angers, Bordeaux, Brest, Lyon, Marseille, Montpellier, Tours

2024-03-05

Recruiting

French Assessment of MRD by Liquid Biopsies in PDAC Patients (FRENCH.MRD.PDAC)

NCT06287749Pancreatic Cancer Resectable, Pancreatic Ductal Adenocarcinoma, Minimal Residual Disease, Liquid Biopsy

DrugBlood sample/Liquid biopsy

University Hospital, Montpellier

Observational

Montpellier

2024-03-01

Recruiting

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT06161025Solid Cancer

DrugsR-DXd·Topotecan·Paclitaxel

Daiichi Sankyo

Phase 2/3

860

Bordeaux, Caen, Clermont-Ferrand, Dijon, Lyon, Marseille, Montpellier, Nantes

2024-02-27

Recruiting

Adapted Physical Activity Program (APA) for Effort Rehabilitation of Children and Teenagers With Osteogenesis Imperfecta

NCT05927389Osteogenesis Imperfecta

University Hospital, Toulouse

Not applicable

Montpellier, Toulouse

2024-02-26

Active, closed

Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)

NCT05925530Non-small Cell Lung Cancer

DrugDurvalumab

AstraZeneca

Phase 2

142

La Tronche, Marseille, Montpellier, Mulhouse, Paris, Pessac, Poitiers, Toulouse

2024-02-22

Active, closed

A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy

NCT05979311HIV, HIV Infections

DrugsBictegravir·Dolutegravir·Emtricitabine·Lamivudine

ViiV Healthcare

Phase 3

463

Bordeaux, Lyon, Montpellier, Nice, Nîmes, Paris

2024-02-21

Active, closed

A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer

NCT06012435Carcinoma, Non-Small-Cell Lung

DrugsSigvotatug vedotin·Docetaxel

Seagen, a wholly owned subsidiary of Pfizer

Phase 3

762

Besançon, Cholet, Créteil, Lille, Marseille, Montpellier, Paris, Pessac

2024-02-21

Active, closed

Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib in Adult Participants With Moderate to Severe Crohn's Disease (CD) in Real World Clinical Practice.

NCT05930275Crohn's Disease

AbbVie

Observational

1,200

Nice, Clermont, Lyon, Marseille, Dijon, Pessac, Toulouse, Montpellier

2024-02-19

Active, closed

A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.

NCT06206837Breast Cancer

DrugsVepdegestrant·Atirmociclib

Pfizer

Phase 1/2

Montpellier, Saint-Herblain, Marseille

2024-02-19

Recruiting

EGEA4 THE 30 YEAR FOLLOW UP OF THE EGEA STUDY

NCT06334705Healthy Volunteer EGEA4 Cohort

Institut National de la Santé Et de la Recherche Médicale, France

Not applicable

1,000

Grenoble, Lyon, Marseille, Montpellier, Paris

2024-02-15

Recruiting

Advantages of Early Intrauterine Transfer of "Blank" Culture Medium Prior to 1st or 2nd Transfer of Thawed Embryo(s).

NCT06177613Single Embryo Transfer, Fertilization in Vitro

Centre Hospitalier Universitaire de Nīmes

Not applicable

1,154

Clamart, Contamine-sur-Arve, Montpellier, Nîmes, Perpignan

2024-02-09

Recruiting

Evaluation of Integrated Versus Parallel Connection for Renal Replacement Therapy in ECMO Patients

NCT06038162Venoarterial Extracorporeal Membrane Oxygenation, Renal Replacement Therapy, Acute Kidney Injury

Hospices Civils de Lyon

Not applicable

158

Bordeaux, Clermont-Ferrand, Dijon, Grenoble, Lille, Lyon, Montpellier, Paris

2024-02-07

Recruiting

Search for Structural Variants in Patients With DSD and Inconclusive Molecular Diagnosis

NCT05867979Disorder of Sex Development, 46,XY

University Hospital, Montpellier

Not applicable

Montpellier

2024-02-05

Active, closed

A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF

NCT06237335Cystic Fibrosis

DrugIvacaftor

ReCode Therapeutics

Phase 2

128

Montpellier, Paris

2024-02-01

Recruiting

A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

NCT06004245Advanced Solid Tumors, Colorectal Cancer

DrugsVVD-133214·Avastin·Keytruda·Bevacizumab

Vividion Therapeutics, Inc.

Phase 1

280

Lyon, Montpellier, Paris, Toulouse, Villejuif

2024-01-25

Recruiting

DEWI: Watch-and-Wait With Dostarlimab in Localized dMMR/MSI-H Gastric/GEJ Adenocarcinoma Phase II Study

NCT06059495Adenocarcinoma - GEJ, Gastric Adenocarcinoma

DrugDostarlimab

GERCOR - Multidisciplinary Oncology Cooperative Group

Phase 2

Besançon, Bordeaux, Brest, Créteil, Lille, Lyon, Marseille, Montpellier

2024-01-22

Recruiting

PASCA-MM Study. Impact of the PASCA (PArcours de Santé au Cours du CAncer) Program on Complications Associated With Multiple Myeloma and/or Its Treatments in the Context of a First Hematopoietic Stem Cell Autograft, in Adults Aged 18 to 70.

NCT05947136Multiple Myeloma, Complication

Centre Leon Berard

Not applicable

204

Épagny, Grenoble, Lyon, Montpellier, Saint-Etienne, Villefranche-sur-Saône

2024-01-19

Active, closed

A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

NCT06018337Metastatic Breast Cancer

DrugsDB-1303/BNT323·Nab-paclitaxel·Capecitabine·Paclitaxel

DualityBio Inc.

Phase 3

541

Marseille, La Rochelle, Besançon, Nîmes, Bordeaux, Toulouse, Limoges, Montpellier

2024-01-18

Active, closed

Study of ALXN2220 Versus Placebo in Adults With ATTR-CM

NCT06183931Transthyretin Amyloid Cardiomyopathy

DrugCliramitug

Alexion Pharmaceuticals, Inc.

Phase 3

1,182

Bron, Chambray-lès-Tours, Créteil, Marseille, Montpellier, Paris, Pessac, Poitiers

2024-01-11

Recruiting

A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

NCT06090539Relapsed/Refractory Non-Hodgkin Lymphoma

DrugsGolcadomide·Mosunetuzumab·Epcoritamab·Truxima

Bristol-Myers Squibb

Phase 1/2

460

Bordeaux, Lyon, Lille, Villejuif, Créteil, Montpellier, Paris, Toulouse

2023-12-29

Active, closed

Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma

NCT05948475Cholangiocarcinoma

DrugTinengotinib

TransThera Sciences (Nanjing), Inc.

Phase 3

200

Avignon, Besançon, Clichy, Levallois-Perret, Lyon, Montpellier, Paris, Villejuif

2023-12-20

Recruiting

Safety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma

NCT06016920HPV Positive Oropharyngeal Squamous Cell Carcinoma, HNSCC

DrugsKeytruda·Pembrolizumab

Nykode Therapeutics ASA

Phase 1/2

110

Montpellier, Paris

2023-12-19

Recruiting

A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment

NCT05828511Multiple Myeloma

DrugLinvoseltamab

Regeneron Pharmaceuticals

Phase 1/2

149

Poitiers, Lille, Montpellier, Paris, Antony, Villejuif

2023-12-19

Recruiting

Precision Imaging for Early Detection and Targeted Treatment Monitoring in Pancreatic Cancer

NCT06144762Pancreas Cancer

Institut du Cancer de Montpellier - Val d'Aurelle

Not applicable

150

Montpellier

2023-12-19

Recruiting

Tucatinib in Combination With Oral Etoposide andTrastuzumab in Patients With Metastatic HER2+ Breast Cancer

NCT05955170HER2-positive Breast Cancer

Institut Curie

Phase 2

Clermont-Ferrand, Amiens, Avignon, Caen, Dijon, Lille, Montpellier, Nantes

2023-12-19

Recruiting

Unravelling Tumour Biology In Ovarian Cancer With Precision Imaging

NCT06084195High Grade Serous Ovarian Cancer

Institut du Cancer de Montpellier - Val d'Aurelle

Not applicable

120

Montpellier

2023-12-19

Recruiting

Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal Disease

NCT05800275Leptomeningeal Metastasis, Leptomeningeal Disease, HER2-positive Metastatic Breast Cancer

DrugsTucatinib·Trastuzumab·Capecitabine

UNICANCER

Phase 2

Bordeaux, Caen, Clermont-Ferrand, Dijon, Lyon, Montpellier, Nice, Reims

2023-12-18

Recruiting

Efficiency of a Composite Personalised Care on Functional Outcome in Early Psychosis

NCT05796401Psychosis

Centre Hospitalier St Anne

Phase 3

500

Brest, Caen, Clermont-Ferrand, Dijon, Lille, Montpellier, Nancy, Orsay

2023-12-15

Recruiting

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

NCT06170788Non-small Cell Lung Cancer (NSCLC)

DrugsSacituzumab tirumotecan·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

614

Marseille, Montpellier, Limoges, Nancy, Bayonne, Villefranche-sur-Saône, Amiens, Poitiers

2023-12-15

Recruiting

Azathioprine in MOGAD

NCT05349006Central Nervous System Inflammation, MOG-IgG Associated Disease

DrugAzathioprine

Hospices Civils de Lyon

Phase 3

126

Bordeaux, Lille, Lyon, Marseille, Montpellier, Nancy, Nice, Nîmes

2023-12-12

Recruiting

Long Term Follow-up of the TREOCAPA Study (TREOCAPA-LT)

NCT06064825Patency of the Ductus Arteriosus Acetaminophen Extreme Prematurity

Institut National de la Santé Et de la Recherche Médicale, France

Observational

500

Angers, Bron, Montpellier, Nantes, Paris, Strasbourg, Tours

2023-12-12

Recruiting

Salivary Biomarkers for Concussion

NCT06149351Sport Related Concussion

Sys2Diag

Observational

Montpellier

2023-12-12

Recruiting

Immunity After Cochlear Implantation and Perilymph Molecular Profiles in Sensorineural Hearing Loss

NCT05670158Sensorineural Hearing Loss

DrugBlood sampling

University Hospital, Montpellier

Not applicable

Montpellier

2023-12-07

Active, closed

A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines

NCT05976243Chronic Inducible Urticaria

DrugRemibrutinib

Novartis Pharmaceuticals

Phase 3

362

Grenoble, Montpellier, Nantes, Paris, Pierre-Bénite, Rouen, Toulouse

2023-12-07

Active, closed

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

NCT06077760Non-small Cell Lung Cancer

DrugsIntismeran autogene·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

868

Strasbourg, Pessac, Marseille, Caen, Montpellier, Angers, Clermont-Ferrand, Paris

2023-12-06

Active, closed

Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)

NCT06132958Endometrial Cancer

DrugsAbraxane·Adriamycin·Sacituzumab tirumotecan·Taxol

Merck Sharp & Dohme LLC

Phase 3

710

Bordeaux, Lyon Cedex08, Chambray-lès-Tours, Plérin, Besançon, Toulouse, Lille, Montpellier

2023-12-06

Active, closed

Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis

NCT06029972Ulcerative Colitis

Gilead Sciences

Phase 2

176

Grenoble, Little Cedex, Montpellier, Nantes, Neuilly-sur-Seine, Saint-Etienne, Toulouse, Vandœuvre-lès-Nancy

2023-12-05

Active, closed

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

NCT06109779Biliary Tract Cancer

DrugsGemcitabine/Cisplatin·Rilvegostomig·Teysuno·Capecitabine

AstraZeneca

Phase 3

760

Marseille, Montpellier, Pessac, Rennes, Strasbourg, Toulouse, Villejuif

2023-12-04

Recruiting

Screening for Neurodevelopmental Disorders in Siblings of Children With Autism Diagnosed in Tertiary Centers

NCT05512637Autism Spectrum Disorder, Siblings, Neurodevelopmental Disorders

University Hospital, Montpellier

Observational

384

Montpellier

2023-11-28

Recruiting

A Study to Evaluate Pre-operative HYPOfractionated Radiation Therapy in Aged (≥ 70 Years Old) or "Fragile" (≥ 65 Years) Patients With Limb or Trunk Soft Tissue SARComa.

NCT06022159Soft Tissue Sarcoma

Institut Claudius Regaud

Phase 2

Bordeaux, Lille, Limoges, Lyon, Montpellier, Paris, Poitiers, Saint-Herblain

2023-11-28

Recruiting

Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.

NCT05948943Lymphatic Malformations

DrugAlpelisib

Novartis Pharmaceuticals

Phase 2/3

232

Angers, Bordeaux, Bron, Caen, Dijon, Lille, Marseille, Montpellier

2023-11-24

Recruiting

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

NCT06103864Breast Cancer

DrugsDato-DXd·Durvalumab·Nab-paclitaxel·Gemcitabine

AstraZeneca

Phase 3

625

Lille, Lyon, Montpellier, Paris, Saint-Herblain, Toulouse, Vandœuvre-lès-Nancy, Villejuif

2023-11-23

Recruiting

Development of Targeted RNA-Seq for Amyotrophic Lateral Sclerosis Diagnosis

NCT06083584Amyotrophic Lateral Sclerosis

Centre Hospitalier Universitaire de Nīmes

Observational

192

Bordeaux, Clermont-Ferrand, Lyon, Marseille, Montpellier, Nîmes, Toulouse

2023-11-22

Recruiting

Evaluation of the Valiant Captivia Physician Fenestrated Stent Graft System in Aortic Arch and Descending Thoracic Aorta Pathologies

NCT05479305Penetrating Ulcer of Aorta, Aneurysm Aortic, Type B Aortic Dissection, Residual Dissection After Type A Repair

Ceric Sàrl

Not applicable

Brest, Bron, Montpellier, Orléans

2023-11-21

Active, closed

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents

NCT06120491Metastatic Castration-Sensitive Prostate Cancer

DrugsSaruparib·Zytiga·Xtandi·Abiraterone acetate

AstraZeneca

Phase 3

1,898

Angers, Bayonne, Bordeaux, Caen, Clermont-Ferrand, Créteil, Lyon, Montpellier

2023-11-21

Recruiting

Study of Families With an Hemopathies Predisposition Related to the DDX41 Gene.

NCT06022016DDX41 Gene Mutation

Institut Claudius Regaud

Not applicable

910

Bordeaux, Limoges, Marseille, Montpellier, Toulouse

2023-11-17

Recruiting

Anatomical-Clinical Base of Adenocarcinoma Pancreatic

NCT06128343Adenocarcinoma, Carcinoma, Neoplasms

University Hospital, Toulouse

Observational

1,500

Béthune, Bordeaux, Lille, Lyon, Montpellier, Pau, Toulouse

2023-11-16

Recruiting

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

NCT06128551Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma

DrugsElironrasib·Cetuximab

Revolution Medicines, Inc.

Phase 1/2

534

Angers, Bordeaux, Bron, Lille, Lyon, Montpellier, Nantes, Strasbourg

2023-11-14

Active, closed

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

NCT06112379Breast Cancer

DrugsDato-DXd·Epirubicin·Xeloda·Olaparib

AstraZeneca

Phase 3

1,902

Avignon, Bayonne, Caen, Clermont-Ferrand, Limoges, Marseille, Montpellier, Nice

2023-11-14

Recruiting

Adapted Physical Activity in the Treatment of Anorexia:

NCT05477537Anorexia Nervosa

Fondation Santé des Étudiants de France

Not applicable

220

Lille, Lyon, Montpellier, Nantes, Paris, Saint-Etienne

2023-11-14

Active, closed

Trial of Efficacy and Safety of MC0518 Versus Best Available Therapy in Participants With Steroid-Refractory Acute Graft Versus Host Disease

NCT06075706Steroid-refractory Acute Graft-versus-host Disease

DrugMC0518

medac GmbH

Phase 2

Bordeaux, La Tronche, Lille, Lyon, Marseille, Montpellier, Nantes, Paris

2023-11-13

Active, closed

MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma

NCT06097728Unresectable Pleural Mesothelioma

DrugsVolrustomig·Yervoy·Paraplatin·Ipilimumab

AstraZeneca

Phase 3

863

Brest, Créteil, Le Mans, Lille, Lyon, Marseille, Montpellier, Paris

2023-11-09

Active, closed

Permanent Intracranial Stenting for Acute Ischemic Stroke Related to a Refractory Large Vessel Occlusion

NCT06071091Acute Ischemic Stroke

Assistance Publique - Hôpitaux de Paris

Not applicable

346

Amiens, Bordeaux, Créteil, Le Kremlin-Bicêtre, Lille, Montpellier, Nancy, Paris

2023-11-08

Recruiting

Evaluation of the Benefit of a New Surgical Procedure According to IDEAL Recommendations for ORL Cancer Patients: the External Pudendal Flap Used as a New Free Flap for Oral Cavity/Oropharyngeal Reconstruction to Limit Donor Site Sequelae

NCT05757817Head and Neck Cancer, Oral Cavity Cancer, Oropharynx Cancer

Institut Claudius Regaud

Not applicable

Montpellier, Nice, Toulouse

2023-11-08

Recruiting

Predictive Value of Glycemic Parameters Measured With the FSL Pro iQ During ACS

NCT06014112Acute Coronary Syndrome, Continuous Glucose Measurement, Glycemic Variability, Cardiovascular Event

University Hospital, Montpellier

Not applicable

850

Béziers, Bordeaux, Montpellier, Nîmes, Paris, Pau, Toulouse, Vannes

2023-11-06

Active, closed

TheraSphere With Durvalumab and Tremelimumab for HCC

NCT05063565Hepatocellular Carcinoma

Boston Scientific Corporation

Phase 2

100

Rennes, Clichy, Grenoble, Clermont-Ferrand, Créteil, Lille, Montpellier, Nantes

2023-11-03

Recruiting

Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD

NCT05566769Neuromyelitis Optica

Ad scientiam

Not applicable

103

Lille, Marseille, Montpellier, Nice, Paris, Rouen, Strasbourg, Toulouse

2023-11-03

Recruiting

Oral Pooled Fecal Microbiotherapy to Prevent Allogeneic Hematopoietic Cell Transplantation Complications (PHOEBUS Trial)

NCT05762211Transplant Complication

DrugPooled allogeneic fecal microbiotherapy

MaaT Pharma

Phase 2

387

Angers, Besançon, Caen, La Tronche, Lille, Limoges, Marseille, Montpellier

2023-10-31

Recruiting

Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.

NCT05918302Neuroendocrine Tumors, Lung Neuroendocrine Neoplasm, Thymus Neoplasms

Drugs177Lu-edotreotide·Everolimus

Grupo Espanol de Tumores Neuroendocrinos

Phase 3

170

Dijon, Bourdeaux, Lille, Lyon, Marseille, Montpellier, Nantes, Paris

2023-10-27

Active, closed

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

NCT05899608Non-Small Cell Lung Cancer

DrugsIvonescimab·Pembrolizumab

Summit Therapeutics

Phase 3

1,600

Brest, Caen, Créteil, Le Mans, Marseille, Montpellier, Paris, Pierre-Bénite

2023-10-26

Recruiting

A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

NCT06084936Lymphoma

DrugsGlofitamab·Bendamustine·Tocilizumab·Obinutuzumab

Hoffmann-La Roche

Phase 3

182

Lille, Montpellier, Nantes, Paris

2023-10-22

Not yet open

Evaluation of the Efficacy of Immunomodulatory Therapy in Case of Psychiatric Disorders With Proven Dysimmunity.

NCT05946486Mental Disorder

University Hospital, Bordeaux

Phase 3

174

Bordeaux, Bron, Clermont-Ferrand, Colombes, Créteil, Le Kremlin-Bicêtre, Montpellier, Strasbourg

2023-10-15

By invitation

A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

NCT06044337Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus

DrugLitifilimab

Biogen

Phase 3

306

Caen, Toulouse, Montpellier, Lyon, Paris

2023-10-03

Recruiting

Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN

NCT05755386IC-MPGN

DrugIptacopan

Novartis Pharmaceuticals

Phase 3

106

Marseille, Montpellier, Paris, Rennes, Toulouse

2023-10-02

Recruiting

Post-Market Clinical Follow Up Study With Navitor Valve

NCT06008080Aortic Stenosis

Abbott Medical Devices

Observational

1,000

Massy, Montpellier, Paris, Rennes, Toulouse

2023-09-29

Recruiting

Analysis of the Resistance and Sensitivity Mechanisms to Teclistamab by Focusing on Single Immune Cell Examination

NCT05945524Multiple Myeloma

University Hospital, Toulouse

Not applicable

100

Amiens, Caen, Dijon, Epagny Metz- Tessy, Lille, Lyon, Montpellier, Paris

2023-09-28

Active, closed

Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)

NCT05822752Hepatocellular Carcinoma

DrugsLivmoniplimab·Budigalimab·Sorafenib·Lenvatinib

AbbVie

Phase 2

130

Pessac, Montpellier, La Tronche, Lille, Villejuif, Clichy

2023-09-21

Active, closed

An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma

NCT06047080Large B-Cell Lymphoma

DrugsPolatuzumab Vedotin·Glofitamab·Doxorubicin·Prednisone

Hoffmann-La Roche

Phase 3

1,130

Lille, Lyon, Marseille, Montpellier, Nantes, Pessac, Rennes, Rouen

2023-09-18

Recruiting

Hysteroscopy vs. Endouterine Aspiration in the Management of Trophoblastic Retention

NCT05789940Miscarriage

University Hospital, Montpellier

Not applicable

220

Bordeaux, Montpellier, Nice, Nîmes

2023-09-18

Active, closed

A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)

NCT05869955Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, Systemic Sclerosis, Rheumatoid Arthritis

DrugsZola-cel·Tocilizumab·Fludarabine·Cyclophosphamide

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Phase 1

270

Pessac, Montpellier, Lille, Nice, Paris, Rennes

2023-09-13

Recruiting

Montpellier PROspective Cohort in Relapsing Remitting Multiple Sclerosis Using Imaging and Serologic

NCT05962177Multiple Sclerosis

University Hospital, Montpellier

Not applicable

400

Montpellier

2023-09-11

Active, closed

Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine

NCT05846230Bronchiectasis

DrugVerducatib

Boehringer Ingelheim

Phase 2

268

Amiens, Montpellier, Rennes

2023-09-08

Recruiting

Forced Oscillations Technique During a Metacholine Test in Children

NCT05734261Asthma in Children

University Hospital, Montpellier

Not applicable

112

Montpellier

2023-09-07

Active, closed

Enlighten Study: The EV-ICD Post Approval Registry

NCT06048731Ventricular Arrhythmia, Tachycardia

Medtronic

Observational

1,000

Clermont-Ferrand, La Tronche, Lille, Montpellier, Nantes, Paris, Pessac, Rennes

2023-09-01

Active, closed

A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)

NCT06081894Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy

DrugAficamten

Cytokinetics

Phase 3

500

Marseille, Montpellier, Paris, Pessac, Saint-Herblain, Toulouse

2023-08-31

Active, closed

A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis (RENOIR)

NCT06041269Rheumatoid Arthritis

DrugRosnilimab

AnaptysBio, Inc.

Phase 2

420

Cahors, Montpellier, Toulouse

2023-08-31

Active, closed

Combination of PRP and XLHA Prepared With RegenMatrix Medical Device To Treat Moderate to Severe Knee Osteoarthritis

NCT05727371Knee Osteoarthritis

RegenLab France SAS

Not applicable

280

Dijon, Corbeil-Essonnes, Créteil, La Roche-sur-Yon, Limoges, Lyon, Montpellier, Nantes

2023-08-21

Active, closed

Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)

NCT05771480Biliary Tract Cancer

DrugsAlbumin-Bound Paclitaxel·Teysuno·Durvalumab·Oxaliplatin

AstraZeneca

Phase 3

142

Clichy, Dijon, Montpellier, Villejuif

2023-08-16

Recruiting

Aspirin for the Prevention of Preeclampsia and Pregnancy Outcomes After Assisted Reproductive Technology

NCT05625724ART, Pre-Eclampsia

DrugAspirin

University Hospital, Toulouse

Phase 3

1,164

Angers, Bordeaux, Clermont-Ferrand, Dijon, Lille, Lyon, Marseille, Montpellier

2023-08-02

Recruiting

GUIDE.MRD-01-CRC: Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Colorectal Cancer

NCT06111105Colorectal Cancer Stage III, Liver Metastasis Colon Cancer

Claus Lindbjerg Andersen

Observational

590

Montpellier

2023-08-01

Active, closed

Long-term Mortality Post Liver Transplantation in the Era of Modern Immunosuppression.

NCT06636409Liver Transplant

University Hospital, Montpellier

Observational

1,343

Montpellier

2023-08-01

Recruiting

First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors

NCT05828459Hematological Malignancy, Solid Tumor

DrugsIMiDs·Pomalidomide·Lenalidomide·Paclitaxel

Onward Therapeutics

Phase 1

150

Montpellier, Paris, Rennes

2023-07-10

Recruiting

Liver Cancer and Immunotherapy in the Liquid Biopsy Era

NCT05810402Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Immune Checkpoint Inhibitor

University Hospital, Montpellier

Not applicable

Montpellier

2023-06-28

Active, closed

Prospective Observational Study of Effectiveness and Safety of Filgotinib in Participants With Ulcerative Colitis (UC)

NCT05817942Ulcerative Colitis

DrugFilgotinib

Alfasigma S.p.A.

Observational

509

Amiens, Besançon, Clichy, Grenoble, Lille, Montpellier, Nancy, Nantes

2023-06-12

Active, closed

Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies

NCT05753501Hematologic Cancer

DrugVenetoclax

AbbVie

Phase 1

135

Bordeaux, Montpellier, Lille, Nantes, Villejuif, Paris

2023-06-09

Recruiting

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

NCT05646862Breast Cancer

DrugsBupropion·Omeprazole·Alpelisib·Inavolisib

Hoffmann-La Roche

Phase 3

420

Avignon, Bayonne, Bordeaux, Lyon, Montpellier, Rennes, Toulouse

2023-06-07

Recruiting

Study of the Impact of Frequency of Changing PICCline Dressings in Patients With Acute Leukemia

NCT05793801Leukemia

Centre Hospitalier Universitaire de Nīmes

Not applicable

Montpellier

2023-06-06

Recruiting

Impact of an Early Identification Program for First-Episode Psychosis on the Duration of Untreated Psychosis

NCT05813457Psychotic Episode

Centre Hospitalier Universitaire de Saint Etienne

Not applicable

416

Bron, Clermont-Ferrand, Grenoble, Montpellier, Nîmes, Saint-Etienne

2023-06-06

Recruiting

Risk Factors and Progression of Keratoconus

NCT05676580Keratoconus

University Hospital, Montpellier

Not applicable

200

Montpellier

2023-06-05

Recruiting

Routine Versus Symptomatic Protein Pump Inhibitor Therapy for Prevention of Gastroesophageal Reflux After Per Oral Endoscopic Myotomy for Esophageal Achalasia

NCT05899842Esophageal Achalasia

Centre Hospitalier Universitaire de Nīmes

Not applicable

132

Marseille, Montpellier, Nîmes

2023-06-01

Recruiting

A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study

NCT05862285Cancer

DrugsTiragolumab and Atezolizumab·Divarasib·Tiragolumab·Ipatasertib

Hoffmann-La Roche

Phase 3

100

Marseille, Bordeaux, Caen, Dijon, Lyon, Montpellier, Nantes, Nîmes

2023-06-01

Recruiting

Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer

NCT05462613Metastatic Colorectal Cancer

DrugsRegorafenib·Aspirin·Folfox·Bevacizumab

Centre Hospitalier Universitaire de Besancon

Phase 2/3

446

Besançon, Clermont-Ferrand, Créteil, Dijon, Lyon, Montbéliard, Montpellier, Mulhouse

2023-05-09

Active, closed

An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma

NCT05876754Cholangiocarcinoma

DrugIvosidenib

Servier Affaires Médicales

Phase 3

299

Lyon, Marseille, Montpellier, Nantes, Paris, Pessac, Poitiers

2023-05-03

Recruiting

Incidence and Morbidity of Cardiac Rhythm Disorders in Patients Assisted by ECMO-VA for Refractory Cardiogenic Shock

NCT05788120Cardiac Rhythm Disorder

Assistance Publique - Hôpitaux de Paris

Observational

600

Angers, Bron, Caen, Chambray-lès-Tours, Dijon, Grenoble, Lille, Montpellier

2023-04-28

Recruiting

Continuous Electrical Neuromodulation of the Globus Pallidus Intern in Parkinson's Disease by the Directional Electrode CARTESIA™

NCT05626608Parkinson Disease

University Hospital, Montpellier

Not applicable

Montpellier

2023-04-28

Recruiting

OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial

NCT05587894COVID-19, Immunodeficiency

DrugsNirmatrevlir/ritonavir·Veklury·Remdesivir

ANRS, Emerging Infectious Diseases

Phase 2

256

Bordeaux, Dijon, Lyon, Montpellier, Nantes, Paris, Reims, Toulouse

2023-04-27

Active, closed

Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)

NCT05624749Systemic Lupus Erythematosus

DrugIanalumab

Novartis Pharmaceuticals

Phase 3

288

Montpellier, Paris, Toulouse, Tours

2023-04-21

Recruiting

Platform for the Prospective Mother-child Study of the Determinants of Neurodevelopmental Disorders

NCT05681923Autism Spectrum Disorder, Neurodevelopmental Disorders

University Hospital, Montpellier

Observational

7,320

Montpellier

2023-04-19

Active, closed

Balloon-Expandable Versus Self-expanding Transcatheter Heart Valve for Treatment of Symptomatic Native Aortic Valve Stenosis (BEST)

NCT05454150Aortic Valve Stenosis

University Hospital, Lille

Not applicable

1,960

Annecy, Besançon, Caen, Clermont-Ferrand, Créteil, Grenoble, Massy, Montpellier

2023-04-19

Recruiting

Effect of Sedative and Anxiolytic Premedication on Children Experience After General Anesthesia

NCT05681572Anesthesia

DrugsMidazolam·Dexmedetomidine

University Hospital, Montpellier

Phase 3

1,000

Montpellier

2023-04-18

Recruiting

Biomarkers of Sleep-wake Cycle in Prodromal Alzheimer's Disease: Role in Cognitive Decline?

NCT05629871Neuropathology

University Hospital, Montpellier

Not applicable

132

Montpellier, Poitiers, Toulouse

2023-04-17

Recruiting

ProActIF-01 Trial: Feasibility Study of an Individualized Program of Nutrition and Adapted Physical Activity in Frail Patients With Advanced Digestive Cancers

NCT05441163CANCER

Institut Curie

Not applicable

Tours, Avignon, Bordeaux, Clermont-Ferrand, Grenoble, Lille, Lyon, Montpellier

2023-04-08

Recruiting

Cohort of Patients with Alzheimer's Disease and Their Families.

NCT05516667Alzheimer Disease

University Hospital, Toulouse

Observational

1,000

France, Montpellier, Rouen, Toulouse

2023-04-06

Recruiting

A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions

NCT05816382Narcolepsy Type 1

DrugTAK-861

Takeda

Phase 2/3

500

Toulouse, Montpellier, La Tronche, Paris

2023-04-05

Recruiting

COMpassion for Psychiatric Disorders And Self-Stigma

NCT05698589Bipolar Disorder, Schizophrenia, Depression, Borderline Personality Disorder

University Hospital, Strasbourg, France

Not applicable

336

Bordeaux, Bron, Clermont-Ferrand, Laxou, Montpellier, Reims, Strasbourg

2023-04-03

Recruiting

NAlmefene Versus Placebo in Addition to Treatment as Usual on Craving in Behavioural Addictions

NCT05540288Behavioural Addiction

Nantes University Hospital

Phase 3

266

Besançon, Bordeaux, Brest, Clermont-Ferrand, Dijon, La Rochelle, Lyon, Montpellier

2023-03-31

Recruiting

Evaluation of Mobility in Subjects With Severe Knee Osteoarthritis Who Are to Undergo Total Knee Replacement

NCT05488093Knee Osteoarthritis

University Hospital, Montpellier

Not applicable

Montpellier

2023-03-30

Active, closed

A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma

NCT05572515Relapsed or Refractory Multiple Myeloma

DrugsTeclistamab·Carfilzomib·Pomalidomide·Bortezomib

Janssen Research & Development, LLC

Phase 3

614

Amiens, Caen, Grenoble, Le Mans, Lille, Montpellier, Nantes, Paris

2023-03-29

Recruiting

Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence

NCT05310591B Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse

Assistance Publique - Hôpitaux de Paris

Phase 1/2

Bordeaux, Lille, Lyon, Marseille, Montpellier, Nancy, Nantes, Paris

2023-03-15

Active, closed

Symptoms Control and adhErenCe Assessment During Treatment With MepolizUmab New pREfilled Devices

NCT05626777Asthma

Hospices Civils de Lyon

Phase 4

Besançon, Dijon, Lille, Lyon, Montpellier, Paris, Reims, Toulouse

2023-03-09

Active, closed

A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer

NCT05654623Advanced Breast Cancer

DrugsVepdegestrant·Fulvestrant

Pfizer

Phase 3

624

Dijon, Montpellier, Saint-Herblain, Angers, Clermont-Ferrand, Avignon, Poitiers, Créteil

2023-03-03

Active, closed

REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels

NCT05669755Cardiovascular Disease

DrugsCagrilintide·Semaglutide

Novo Nordisk A/S

Phase 3

7,101

Annonay, Bobigny, Grenoble, Le Coudray, Le Havre, Lille, Montpellier, Paris

2023-03-01

Active, closed

Efficacy and Safety of ATX01 in Adult Patients With CIPN (Chemotherapy-induced Peripheral Neuropathy)

NCT05593614Chemotherapy-induced Peripheral Neuropathy

AlgoTherapeutix

Phase 2

276

Bayonne, Bordeaux, Montpellier, Paris, Poitiers, Reims, Strasbourg, Suresnes

2023-02-28

Recruiting

A Safety and Pharmacokinetics Trial of VO659 in SCA1, SCA3 and HD

NCT05822908Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 3, Huntington Disease

Vico Therapeutics B. V.

Phase 1/2

Angers, Montpellier, Paris

2023-02-14

Active, closed

Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma

NCT05605899High-risk Large B-cell Lymphoma (LBCL)

DrugsAxi-cel·Axicabtagene Ciloleucel·Vincristine·Doxorubicin

Kite, A Gilead Company

Phase 3

300

Bordeaux, Cedex Lyon 08, Dijon, Lille, Montpellier, Nice, Paris, Rennes

2023-02-10

Active, closed

A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

NCT05578976Diffuse Large B-Cell Lymphoma

DrugsEpcoritamab·Vincristine·Doxorubicin·Prednisone

Genmab

Phase 3

900

Nice, Clermont, Marseille, Rennes, Dijon, Limoges, Montpellier, La Tronche

2023-02-08

Recruiting

Impact of Orthodontic Treatment on the Temporomandibular Joints (TMJ) Assessed by Modjaw

NCT05710952Temporomandibular Joint Disorders

University Hospital, Montpellier

Not applicable

Montpellier

2023-02-07

Recruiting

Chronic Airway Disease, Mucus Rheology and Exacerbations

NCT04339270Chronic Obstructive Pulmonary Disease

University Hospital, Montpellier

Phase 4

Bordeaux, Montpellier, Toulouse

2023-02-03

Active, closed

GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease

NCT05686551Huntington Disease

Hoffmann-La Roche

Phase 2

301

Angers, Bordeaux, Créteil, Lille, Marseille, Montpellier, Strasbourg, Toulouse

2023-02-03

Recruiting

Immunological Functionnal Test Validation to Predict Melanoma Metastatic Patient Response to Checkpoint Inhibitors

NCT05649683Melanoma (Skin)

Centre Hospitalier Universitaire de Nice

Not applicable

Nice, Montpellier, Lille

2023-01-31

Active, closed

Registry on Percutaneous Electrochemotherapy

NCT05267080Primary Liver Cancer, Secondary Liver Cancer

Cardiovascular and Interventional Radiological Society of Europe

Observational

250

Montpellier, Paris

2023-01-25

Active, closed

Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer

NCT05563220Breast Cancer, Metastatic Breast Cancer

DrugsAlpelisib·Capivasertib·Elacestrant·Everolimus

Stemline Therapeutics, Inc.

Phase 1/2

435

Lyon, Montpellier, Rouen, Toulouse, Villejuif

2023-01-24

Recruiting

SHort Interval Full Two-stage Implant Exchange

NCT05642013Prosthetic-joint Infection

University Hospital, Montpellier

Not applicable

100

Montpellier, Sète

2023-01-23

Active, closed

A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

NCT05608291Melanoma

DrugsFianlimab·Cemiplimab·Keytruda·Pembrolizumab

Regeneron Pharmaceuticals

Phase 3

1,564

Dijon, Besançon, Bordeaux, Toulouse, Lille, Montpellier, La Tronche, Caen

2023-01-16

Active, closed

Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)

NCT05555732Metastatic Non Small Cell Lung Cancer

DrugsDato-DXd·Pemetrexed·Keytruda·Cisplatin

Daiichi Sankyo

Phase 3

1,170

Avignon, Besançon, Bordeaux, France, Lyon, Marseille, Montpellier, Nantes

2023-01-11

Active, closed

Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations

NCT05687266NSCLC

DrugsDato-DXd·Durvalumab·Pemetrexed·Paclitaxel

AstraZeneca

Phase 3

1,350

Brest, Créteil, Gleizé, Montpellier, Nîmes, Paris, Rouen, Saint-Quentin

2022-12-29

Recruiting

COLchicine and Non-enteric Coated Aspirin in the Cardiovascular Outcomes Trial of Patients With Type 2 Diabetes

NCT05633810Diabete Type 2, Cardiovascular Diseases

DrugsColchicine·Aspirin

Montreal Heart Institute

Phase 3

10,000

Luc-la-Primaube, Vannes, Bezouce, Vergèze, Pins-Justaret, Pornic, Poitiers, Montpellier

2022-12-21

Recruiting

Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia

NCT05327894Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia

DrugBlinatumomab

Princess Maxima Center for Pediatric Oncology

Phase 3

160

Amiens, Besançon, Bordeaux, Grenoble, Lille, Lyon, Marseille, Montpellier

2022-12-15

Active, closed

Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial

NCT05581303Atherosclerotic Cardiovascular Disease

DrugOlpasiran

Amgen

Phase 3

7,297

Besançon, Bron, Chambray-lès-Tours, Compiègne, Dijon, Lille, Marseille, Montpellier

2022-12-14

Recruiting

Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen

NCT05624450Viral Lung Infection and Acute Respiratory Failure

DrugTozorakimab

AstraZeneca

Phase 3

3,527

Amiens, Angers, Brest, Créteil, Dijon, La Tronche, Le Coudray, Montpellier

2022-12-13

Active, closed

CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)

NCT05681351Severe Hypertriglyceridemia

DrugOlezarsen

Ionis Pharmaceuticals, Inc.

Phase 3

885

Bron, Dijon, Marseille, Montpellier, Paris, Saint-Herblain, Strasbourg, Valenciennes

2022-12-13

Active, closed

A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)

NCT05668988Non-small Cell Lung Cancer

DrugsSunvozertinib·Pemetrexed·Carboplatin

Dizal Pharmaceuticals

Phase 3

324

Angers, Bron, Créteil, Hellemmes-Lille, La Tronche, Marseille, Montpellier, Paris

2022-12-13

Active, closed

Carmat Total Artificial Heart as a Bridge to Transplant in Patients With Advanced Heart Failure

NCT04475393Advanced Heart Failure

Carmat SAS

Not applicable

104

Bron, Dijon, Le Plessis-Robinson, Lille, Montpellier, Nantes, Paris, Rennes

2022-12-12

Recruiting

Basal Plasma Lithium Levels and Suicidal Events

NCT05409794Major Depressive Disorder, Suicidal Behavior, Bipolar Disorder

DrugBlood sample

University Hospital, Montpellier

Observational

158

Montpellier

2022-12-09

Active, closed

An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib

NCT05513001Chronic Spontaneous Urticaria

DrugRemibrutinib

Novartis Pharmaceuticals

Phase 3

696

Angers, Antony, Bordeaux, Brest, Montpellier, Nice, Paris, Pierre-Bénite

2022-12-09

Recruiting

Ovarian Reserve and Semen Parameters Evolution During Adjuvant Therapy in Melanoma

NCT05429138Melanoma

Assistance Publique Hopitaux De Marseille

Observational

Bordeaux, Marseille, Montpellier, Nantes, Nice, Nîmes, Paris, Toulouse

2022-12-07

Active, closed

Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.

NCT05445843Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation

DrugOpnurasib

Novartis Pharmaceuticals

Phase 2

Marseille, Bron, Montpellier, Saint-Herblain, Strasbourg

2022-12-06

Active, closed

Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors

NCT05599984Advanced Solid Tumors

DrugsABBV-706·Budigalimab·Cisplatin·Carboplatin

AbbVie

Phase 1

288

Bordeaux, Villejuif, Montpellier

2022-12-05

Recruiting

Study of Gut Microbiota Diversity in Children Aged 1-3 Years on Prolonged Antibiotic Prophylaxis for Grade 3 or Higher Vesicoureteral Reflux Compared With 2 Age-matched Control Groups

NCT05319067Vesicoureteral Reflux 3

Centre Hospitalier Universitaire de Nīmes

Observational

150

Montpellier, Nîmes

2022-12-02

Active, closed

A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

NCT05629585Breast Cancer

DrugsDato-DXd·Xeloda·Durvalumab·Keytruda

AstraZeneca

Phase 3

1,174

Angers, Bordeaux, Dijon, Lyon, Montpellier, Nîmes, Paris, Poitiers

2022-11-28

Recruiting

Efficacy of a Sequential Treatment Strategy in Rheumatoid Arthritis

NCT05428488Rheumatoid Arthritis

DrugAbatacept

University Hospital, Montpellier

Phase 3

220

Montpellier, Bordeaux, Brest, Cahors, La Roche-sur-Yon, Le Mans, Nantes, Nice

2022-11-28

Active, closed

Venetoclax in Patients With MDS or AML in Relapse After AHSCT

NCT05226455MDS, AML

DrugsDonor lymphocyte·Azacitidine·Venetoclax

Groupe Francophone des Myelodysplasies

Phase 1/2

Angers, Grenoble, Limoges, Montpellier, Nantes, Nice, Paris, Pessac

2022-11-23

Active, closed

Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del

NCT05331183Cystic Fibrosis

DrugsELX/TEZ/IVA·Ivacaftor·Elexacaftor/Tezacaftor/Ivacaftor

Vertex Pharmaceuticals Incorporated

Phase 3

297

Bron, Créteil, Lille, Marseille, Montpellier, Nantes, Nice, Paris

2022-11-23

Active, closed

A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)

NCT05394116Fibrodysplasia Ossificans Progressiva

DrugGaretosmab

Regeneron Pharmaceuticals

Phase 3

Montpellier, Paris

2022-11-21

Recruiting

Contact Aspiration Versus Stent Retriever for Recanalisation of Acute Stroke Patients With Basilar Artery Occlusion: The Posterior Circulation ASTER Randomized Trial Protocol

NCT05320263Basilar Artery Occlusion

Hopital Foch

Not applicable

480

Bordeaux, Caen, Limoges, Montpellier, Nancy, Nantes, Paris, Reims

2022-11-19

Active, closed

Dazucorilant in Patients With Amyotrophic Lateral Sclerosis

NCT05407324Amyotrophic Lateral Sclerosis

Corcept Therapeutics

Phase 2

279

Bron, Lille, Limoges, Marseille, Montpellier, Nice, Paris, Tours

2022-11-15

Recruiting

Evaluation of Emotion-related Salivary Molecular Biomarkers

NCT07320040Emotion

Sys2Diag

Observational

240

Montpellier

2022-11-14

Recruiting

A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria

NCT05457283Chronic Kidney Disease, Proteinuria, Children

DrugFinerenone

Bayer

Phase 3

100

Bordeaux, Toulouse, Bron, Montpellier, Strasbourg, Paris

2022-11-08

Active, closed

A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy

NCT05444257Cystic Fibrosis

DrugVNZ/TEZ/D-IVA

Vertex Pharmaceuticals Incorporated

Phase 3

822

Bordeaux, Bron, Créteil, Lille, Montpellier, Nice, Paris, Pierre-Bénite

2022-11-08

Recruiting

Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma

NCT05607420B-cell Non-Hodgkin Lymphoma (B-NHL)

DrugAlemtuzumab

Cellectis S.A.

Phase 1/2

Pierre-Bénite, Montpellier, Nantes, Paris

2022-11-01

Active, closed

A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer

NCT05587296Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer, Hot Flashes

Bayer

Phase 3

474

Lyon, Strasbourg, Bordeaux, Caen, Montpellier, Angers, Saint-Herblain, Paris

2022-10-14

Active, closed

A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment

NCT05455320Multiple Myeloma

DrugsTalquetamab·Pomalidomide·Daratumumab·Dexamethasone

Janssen Research & Development, LLC

Phase 3

864

Créteil, Dijon, Lyon, Montpellier, Nantes, Nice, Paris, Pessac

2022-10-13

Active, closed

Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer

NCT05502237Non-small Cell Lung Cancer

DrugsDomvanalimab·Zimberelimab·Nab-paclitaxel·Pemetrexed

Gilead Sciences

Phase 3

1,021

Boulogne-Billancourt, Le Mans, Marseille, Montpellier, Saint-Herblain, Saint-Mandé, Saint-Quentin, Suresnes

2022-10-12

Active, closed

A Cohort Study of Use of Doravirine (DOR) Based Regimens in Clinical Practice in Europe DoRavirine Europe Real World/

NCT05421806HIV I Infection

NEAT ID Foundation

Observational

500

Montpellier, Nantes, Nice, Paris

2022-10-10

Recruiting

Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma

NCT05528952Hepatocellular Carcinoma

DrugsUCPVax·Atezolizumab·Bevacizumab

Centre Hospitalier Universitaire de Besancon

Phase 2

105

Besançon, Chalon-sur-Saône, Créteil, Dijon, Montbéliard, Montpellier, Mulhouse, Nantes

2022-09-27

Active, closed

Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma

NCT05371093Relapsed/Refractory Follicular Lymphoma

DrugsAxi-cel·Axicabtagene Ciloleucel·Bendamustine·Vincristine

Kite, A Gilead Company

Phase 3

231

Créteil, Dijon, Lille, Marseille, Montpellier, Paris, Pessac, Pierre-Bénite

2022-09-22

Active, closed

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

NCT05242484Colitis, Ulcerative

DrugsJNJ-78934804·Golimumab·Guselkumab

Janssen Research & Development, LLC

Phase 2

577

Amiens, Colombes, Créteil, Grenoble, La Roche-sur-Yon, Lille, Marseille, Montpellier

2022-09-19

Active, closed

A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy

NCT05450692Advanced or Metastatic Non-Small Cell Lung Cancer

DrugsCeralasertib·Durvalumab·Docetaxel

AstraZeneca

Phase 3

594

Angers, Clamart, Clermont-Ferrand, Créteil, Lyon, Montpellier, Nantes, Paris

2022-09-15

Recruiting

Metronomic Chemotherapy in Wilms Tumor (MetroWilms-1906)

NCT05384821Wilms Tumor

DrugsTemozolomide·Vincristine·Irinotecan·Etoposide

Centre Oscar Lambret

Phase 1/2

Amiens, Besançon, Bordeaux, Grenoble, Lille, Lyon, Marseille, Montpellier

2022-09-14

Active, closed

A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

NCT05528510Colitis, Ulcerative

DrugsGuselkumab 1·Guselkumab 2·Guselkumab 3

Janssen Research & Development, LLC

Phase 3

418

Besançon, Le Kremlin-Bicêtre, Montpellier, Neuilly-sur-Seine, Nice, Nîmes, Pessac, Pierre-Bénite

2022-09-13

Active, closed

A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

NCT05531565Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus

DrugLitifilimab

Biogen

Phase 2/3

450

Nice, Marseille, Caen, Besançon, Toulouse, Antony, Montpellier, Lille

2022-09-13

Active, closed

A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT05057494Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

DrugsAcalabrutinib·Obinutuzumab·Venetoclax

AstraZeneca

Phase 3

607

Montpellier, Tours

2022-09-12

Recruiting

Modifying Factors in Striated Muscle Laminopathies

NCT05394506Laminopathies, Emery Dreifuss Muscular Dystrophy 2, LMNA-Related Congenital Muscular Dystrophy, Dilated Cardiomyopathy-1A

Institut National de la Santé Et de la Recherche Médicale, France

Not applicable

Bron, Paris, Montpellier, Rennes, Nantes, Rouen, Garches

2022-09-08

Recruiting

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

NCT05243797Multiple Myeloma

DrugsTeclistamab·Lenalidomide

European Myeloma Network B.V.

Phase 3

1,594

Bordeaux, Lille, Marseille, Montpellier, Nantes, Paris, Poitiers, Toulouse

2022-09-08

Recruiting

Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

NCT05386108Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms

DrugsElacestrant·Abemaciclib

Stemline Therapeutics, Inc.

Phase 1/2

Angers, Brest, Caen, Clermont-Ferrand, Lyon, Montpellier, Paris, Poitiers

2022-08-31

Active, closed

A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

NCT05399888Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia

Biogen

Phase 2

416

Strasbourg, Toulouse, Montpellier, Saint-Herblain, Lille, Paris, Rouen

2022-08-24

Recruiting

Glycosylation Analysis of Lupus Anti-DNA Antibodies (GALA)

NCT05394922Lupus Erythematosus Disseminatus, Autoimmune Diseases, Chronic Disease

University Hospital, Montpellier

Observational

140

Montpellier, Nîmes

2022-08-23

Recruiting

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

NCT05137054Multiple Myeloma

DrugsNirogacestat·Cevostamab·Fianlimab·Linvoseltamab

Regeneron Pharmaceuticals

Phase 1

317

Poitiers, Lille, Nantes, Angers, Montpellier, Paris, Villejuif, Créteil

2022-08-17

Recruiting

A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)

NCT05489705Obstructive Hypertrophic Cardiomyopathy

DrugMavacamten

Bristol-Myers Squibb

Observational

1,700

Haguenau, Saint-Herblain, Lille, Amiens, Toulon, Poitiers, Montpellier

2022-08-16

Active, closed

An Observational Study to Assess Change in Disease Activity and Adverse Events of Upadacitinib in Adult Participants With Moderate to Severe Ulcerative Colitis (UC) in Real-World Practice

NCT05494606Ulcerative Colitis

AbbVie

Observational

785

Nice, Marseille, Besançon, Nîmes, Colmar, Toulouse, Montpellier, La Tronche

2022-08-15

Active, closed

Addiction Intervention in Liver Transplantation Candidates

NCT05322226Transplant; Failure, Liver, Addiction, Alcohol

University Hospital, Montpellier

Not applicable

Montpellier

2022-07-27

Active, closed

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

NCT05382299Triple Negative Breast Cancer, PD-L1 Negative

DrugsAbraxane·Sacituzumab Govitecan·Nab-paclitaxel·Gemcitabine

Gilead Sciences

Phase 3

623

Avignon, Besançon, Brest, Caen, Clermont-Ferrand, Montpellier, Nantes, Pierre-Bénite

2022-07-20

Active, closed

First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Advanced Solid Tumours

NCT05495295Malignant Tumor, Advanced Solid Tumor, Glioblastoma Multiforme, Metastatic Cancer

Phost'In Therapeutics

Phase 1

149

Montpellier

2022-07-18

Recruiting

Impact of Mulstidisciplinary Medication Assessment Review in Surgery Departments

NCT03827031Chronic Disease

Centre Hospitalier Universitaire de Nīmes

Not applicable

297

Grenoble, Montpellier, Nîmes, Toulouse

2022-07-18

Active, closed

A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab

NCT05142696Extensive Stage Small Cell Lung Cancer

Drugs[177Lu]Lu-DOTA-TATE·[68Ga]Ga-DOTA-TATE·Lutathera·Atezolizumab

Novartis Pharmaceuticals

Phase 1/2

Lille, Marseille, Montpellier

2022-07-13

Active, closed

A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer

NCT05217446Metastatic Colorectal Cancer

DrugsEncorafenib·Erbitux·Cetuximab·Keytruda

Pfizer

Phase 2

108

Paris, Clermont-Ferrand, Montpellier

2022-07-11

Active, closed

HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

NCT05338970Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion

DrugPatritumab deruxtecan

Daiichi Sankyo

Phase 3

586

Brest, Caen, Lyon, Montpellier, Paris, Pierre-Bénite, Rennes, Saint-Herblain

2022-07-08

Active, closed

Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

NCT05257408Ovarian Neoplasm, Fallopian Tube Neoplasms, Peritoneal Neoplasms

DrugsNab-paclitaxel /m^2·Relacorilant

Corcept Therapeutics

Phase 3

381

Lille, Montpellier, Nancy, Nice, Paris, Plérin

2022-06-29

Recruiting

Validation of the French Version of the CQR (Compliance Questionnaire Rheumatology)

NCT03642795Rheumatoid Polyarthritis

Centre Hospitalier Universitaire de Nīmes

Observational

150

Bordeaux, Montpellier, Nîmes, Toulouse

2022-06-23

Recruiting

Liquid Biopsy and Pancreas Cancer: Detection of AXL(+) CTCs (CTC-AXL-PANC)

NCT05346536Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Cancer, Circulating Tumor Cell

University Hospital, Montpellier

Not applicable

Montpellier

2022-06-16

Active, closed

A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies

NCT05329766Gastrointestinal Tract Malignancies

DrugsQuemliclustat·Domvanalimab·Zimberelimab·Fluorouracil

Arcus Biosciences, Inc.

Phase 2

332

Bordeaux, Brest, Caen, Lille, Lyon, Marseille, Montpellier, Plérin

2022-06-10

Recruiting

Assessment of Cardiac Coherence Associated With Medical Hypnosis on Preoperative Anxiety in Oncological Surgery

NCT05197972Surgery, Oncology

Institut du Cancer de Montpellier - Val d'Aurelle

Not applicable

296

Montpellier, Lyon, Toulouse, Villejuif

2022-06-01

Recruiting

A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB

NCT05183646FSGS

DrugRepagermanium

Dimerix Bioscience Pty Ltd

Phase 3

286

Bordeaux, Créteil, Grenoble, La Roche-sur-Yon, Marseille, Montpellier, Paris, Saint-Priest-en-Jarez

2022-05-30

Active, closed

A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma

NCT05338775Relapsed/ Refractory Multiple Myeloma

DrugsTalquetamab·Teclistamab·Tuoyi

Janssen Research & Development, LLC

Phase 1

Montpellier, Nantes, Poitiers, Toulouse

2022-05-25

Active, closed

A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)

NCT05123703Relapsing-remitting Multiple Sclerosis

DrugsFingolimod·Ocrelizumab

Hoffmann-La Roche

Phase 3

188

Bron, Le Kremlin-Bicêtre, Montpellier, Strasbourg

2022-05-19

Active, closed

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

NCT05374512Breast Cancer

DrugsEribulin·Dato-DXd·Nab-paclitaxel·Capecitabine

AstraZeneca

Phase 3

644

Bordeaux, Dijon, Limoges, Lyon, Marseille, Montpellier, Paris, Rouen

2022-05-16

Recruiting

Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRC

NCT05310643Metastatic Colorectal Cancer

DrugsYervoy·Ipilimumab·Opdivo·Nivolumab

GERCOR - Multidisciplinary Oncology Cooperative Group

Phase 2

Besançon, Bordeaux, Lille, Limoges, Lyon, Montpellier, Nice, Paris

2022-05-05

By invitation

Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab

NCT05303532Cancer

DrugDurvalumab

AstraZeneca

Phase 3

214

Besançon, Bordeaux, Brest, Dijon, Lyon, Marseille, Montpellier, Rennes

2022-04-19

Active, closed

A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

NCT05288166Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs

DrugsAbiraterone·Abemaciclib·Prednisolone·Prednisone

Eli Lilly and Company

Phase 3

925

Lyon, Brest, La Chaussée-Saint-Victor, Dijon, Besançon, Montpellier, Nantes, Saint-Herblain

2022-04-14

Active, closed

A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria

NCT05196035Chronic Kidney Disease, Proteinuria

DrugFinerenone

Bayer

Phase 3

219

Bron, Strasbourg, Bordeaux, Montpellier, Toulouse, Paris

2022-03-28

Active, closed

Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC

NCT05301842Hepatocellular Carcinoma

DrugsTremelimumab·Durvalumab·Lenvatinib

AstraZeneca

Phase 3

760

Angers, Clichy, Créteil, Montpellier, Nantes, Nice, Paris, Strasbourg

2022-03-28

Recruiting

A Study Comparing the Effectiveness of EndoRotor Versus Radiofrequency in Treating Barrett's Esophagus

NCT04867590Barrett Esophagus, Dysplasia

University Hospital, Angers

Not applicable

140

Besançon, Brest, Chambray-lès-Tours, Dijon, Lille, Limoges, Lyon, Montpellier

2022-03-25

Active, closed

Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT05348577Prostate Cancer

DrugsCapivasertib·Docetaxel

AstraZeneca

Phase 3

1,035

Bordeaux, Brest, Clermont-Ferrand, Créteil, Montpellier, Paris, Rouen, Saint-Herblain

2022-03-25

Recruiting

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

NCT04928846Non Small Cell Lung Cancer, c-MET

DrugsTelisotuzumab vedotin·Docetaxel

AbbVie

Phase 3

768

Marseille, Lille, Montpellier, Pessac, Paris, Avignon, Bron, Lyon

2022-03-25

Active, closed

MaaT013 As Salvage Therapy in Ruxolitinib Refractory GI-aGVHD Patients

NCT04769895Acute Graft Versus Host Disease in Intestine, Steroid Refractory GVHD

MaaT Pharma

Phase 3

Amiens, Angers, Caen, Grenoble, Lille, Marseille, Montpellier, Nice

2022-03-25

Active, closed

Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

NCT05477576GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors

DrugsRYZ101·Octreotide·Lanreotide·Sunitinib

RayzeBio, Inc.

Phase 3

343

Clichy, Lille, Montpellier, Nantes, Vandœuvre-lès-Nancy, Villejuif

2022-03-24

Active, closed

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

NCT05100862Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma

DrugsRuxience·Truxima·Zanubrutinib·Obinutuzumab

BeOne Medicines

Phase 3

799

Antony, Le Mans, Montpellier, Nice, Paris, Strasbourg, VandoeuvrelesNancy

2022-03-10

Active, closed

Research of Circulating Tumor Cells Released During Cervical Cancer Surgery

NCT04770090Cervical Cancer Stage IA1, Cervical Cancer Stage IB1, Cervical Cancer Stage IA2, Cervical Cancer Stage IB2

University Hospital, Montpellier

Not applicable

200

Montpellier, Nîmes

2022-03-10

Active, closed

Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

NCT05280470Extensive-stage Small-cell Lung Cancer

DrugIfinatamab Deruxtecan

Daiichi Sankyo

Phase 2

187

Créteil, Lyon, Marseille, Montpellier, Paris

2022-03-09

Recruiting

Venetoclax Resistance Landscape in Chronic Lymphocytic Leukemia

NCT05246345Chronic Lymphocytic Leukemia, CLL, Progressive Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia

University Hospital, Clermont-Ferrand

Observational

Amiens, Besançon, Bobigny, Clermont-Ferrand, Grenoble, Lille, Lyon, Montpellier

2022-03-07

Active, closed

A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

NCT05132582HER2 Positive Breast Cancer

DrugsPerjeta·Tucatinib·Herceptin·Pertuzumab

Seagen, a wholly owned subsidiary of Pfizer

Phase 3

654

Rouen, Bordeaux, Montpellier, Saint-Herblain, Avignon, Dijon, Besançon, Bobigny

2022-03-07

Recruiting

MITOMICS : a Multi-OMICS Approach for the Diagnosis of Mitochondrial Diseases

NCT04920812Mitochondrial Diseases

Centre Hospitalier Universitaire de Nice

Observational

Nice, Brest, Nantes, Angers, Marseille, Montpellier

2022-03-07

Active, closed

Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations

NCT05215340Metastatic Non Small Cell Lung Cancer

DrugsDato-DXd·Keytruda·Pembrolizumab

Daiichi Sankyo

Phase 3

740

Avignon, Bordeaux, Lille, Lyon, Marseille, Montpellier, Nantes, Paris

2022-03-04

Recruiting

Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects

NCT05156398Migraine

DrugRimegepant

Pfizer

Phase 3

640

Créteil, Montpellier, Toulouse

2022-02-28

Active, closed

A Phase III Study of JR-141 in Patients With Mucopolysaccharidosis II (STARLIGHT)

NCT04573023Mucopolysaccharidosis II

DrugsIdursulfase·JR-141

JCR Pharmaceuticals Co., Ltd.

Phase 3

Lyon, Montpellier, Paris

2022-02-14

Active, closed

Impact of 18F-FES PET on the Therapeutic Treatment of Patients With Metastatic Breast Cancer

NCT05486182Metastatic Breast Cancer

GE Healthcare

Phase 4

153

Dijon, La Tronche, Limoges, Lyon, Montpellier, Neuilly-sur-Seine, Nice, Paris

2022-02-08

Active, closed

A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer

NCT05221840Non-Small Cell Lung Cancer

DrugsMonalizumab·Oleclumab·Durvalumab

AstraZeneca

Phase 3

1,051

Avignon, Besançon, Bordeaux, Clermont-Ferrand, Créteil, Lorient, Marseille, Montpellier

2022-02-07

Recruiting

Selective Internal Radiation Therapy and Capecitabine (Chemotherapy) Treatment for Liver Cancer

NCT05265208Resectable Intrahepatic Cholangiocarcinoma

DrugCapecitabine

Center Eugene Marquis

Phase 2

Rennes, Pessac, Montpellier, Poitiers, Villejuif, Clichy, Créteil

2022-02-04

Active, closed

Study Assessing Long-term Safety and Efficacy of Alpelisib in Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Previously Participated in Study CBYL719F12002 (EPIK-P1)

NCT04980833PIK3CA-related Overgrowth Spectrum (PROS)

DrugAlpelisib

Novartis Pharmaceuticals

Phase 2

Dijon, Montpellier, Paris

2022-01-27

Recruiting

New Clinical End-points in Patients With Primary Sjögren's Syndrome

NCT05113004Primary Sjögren's Syndrome (pSS)

DrugsLeflunomide·Mycophenolate Mofetil·Hydroxychloroquine

Assistance Publique - Hôpitaux de Paris

Phase 2

300

Brest, Lille, Montpellier, Paris, Strasbourg, Talence, Le Kremlin-Bicêtre

2022-01-20

Recruiting

Efficacy of Gembrax Followed by Folfirinox Versus Folfirinox Alone in First Metastatic Line Pancreatic Cancer Patients

NCT05065801Metastatic Pancreatic Cancer

Institut du Cancer de Montpellier - Val d'Aurelle

Phase 2

162

Grenoble, Saint-Etienne, Reims, Montpellier, Perpignan, Dijon

2022-01-11

Active, closed

LIQUID BIOPSY IN Low-grade Glioma Patients

NCT05133154Glioma

DrugBlood samples

University Hospital, Montpellier

Not applicable

Montpellier

2022-01-01

Recruiting

Randomized, Multicenter, Phase III Trial to Assess Conformal Post-operative Radiotherapy vs. Surveillance After Complete Resection of Stage II/III Thymoma (RADIO-RYTHMIC-01)

NCT04731610Thymoma Malignant Recurrent

Institut Curie

Not applicable

314

Caen, Dijon, Lille, Lyon, Marseille, Montpellier, Nice, Paris

2021-12-28

Recruiting

A Clinico-biological Database in Cachexia in Patients With Colon Cancer

NCT05257135Colon Cancer

DrugBiological collection

Institut du Cancer de Montpellier - Val d'Aurelle

Not applicable

150

Montpellier

2021-12-23

Active, closed

Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer

NCT05041842Metastatic Breast Cancer With a Isolated Brain Progression

DrugsPertuzumab/Trastuzumab·Phesgo·Perjeta·Tucatinib

UNICANCER

Phase 2

Angers, Bordeaux, Caen, Dijon, Le Mans, Lyon, Montpellier, Nice

2021-12-17

Active, closed

Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.

NCT05038735Breast Cancer

DrugsAlpelisib·Fulvestrant

Novartis Pharmaceuticals

Phase 3

210

Besançon, Clermont-Ferrand, La Roche-sur-Yon, Lyon, Marseille, Montpellier, Paris, Valenciennes

2021-12-17

By invitation

Long-Term Follow-Up Study After Gene-Modified Cell Treatment in Kite Studies

NCT05041309Solid and Hematological Malignancies, Autoimmune Diseases

DrugsKITE-197·SPRX002·KITE-753·Tecartus

Kite, A Gilead Company

Observational

1,500

Lille, Montpellier, Paris, Pessac, Pierre-Bénite, Rennes

2021-12-15

Active, closed

Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).

NCT05116189Ovarian Cancer, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

DrugsZirabev·Taxotere·Avastin·Docetaxel

Merck Sharp & Dohme LLC

Phase 3

643

Brest, Caen, Limoges, Saint-Cloud, Rennes, Montpellier, Nantes

2021-12-13

Recruiting

Impact of Chronic Renal Failure on Plasma Exposure of Kinase Inhibitors in Patients Treated for Metastatic Kidney Cancer

NCT04823923Kidney Neoplasm

Institut du Cancer de Montpellier - Val d'Aurelle

Not applicable

Marseille, Montpellier, Nîmes, Toulouse

2021-12-06

Active, closed

Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis

NCT05177835Ulcerative Colitis

DrugObefazimod

Abivax S.A.

Phase 2

203

Grenoble, Montpellier, Nantes, Neuilly-sur-Seine, Saint-Etienne

2021-12-03

Recruiting

Study Evaluating the Tailored Management of Locally-advanced Rectal Carcinoma

NCT04749108Locally Advanced Malignant Neoplasm, Rectal Carcinoma

Institut du Cancer de Montpellier - Val d'Aurelle

Phase 2/3

1,075

Marseille, Besançon, Bordeaux, Montpellier, Vandœuvre-lès-Nancy, Nancy, Lille, Amiens

2021-11-26

Recruiting

A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma

NCT05160584Relapsed/Refractory Multiple Myeloma

Janssen Pharmaceutica N.V., Belgium

Observational

300

Lille, Montpellier, Nantes, Pierre-Bénite, Toulouse

2021-11-18

Active, closed

A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

NCT04958265Atypical Hemolytic Uremic Syndrome

DrugCrovalimab

Hoffmann-La Roche

Phase 3

Montpellier, Paris

2021-11-17

Active, closed

A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure

NCT04988295Carcinoma, Non-Small-Cell Lung

DrugsLazertinib·Amivantamab·Pemetrexed·Carboplatin

Janssen Research & Development, LLC

Phase 3

776

Avignon, Bron, La Tronche, Le Mans, Lille, Marseille, Montpellier, Paris

2021-11-17

Recruiting

Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features

NCT05255653Endometrial Cancer

DrugDurvalumab

Leiden University Medical Center

Phase 3

316

Besançon, Bordeaux, Lyon, Marseille, Montpellier, Nice, Saint-Herblain, Strasbourg

2021-11-11

Active, closed

Twin Pregnancy Cohort

NCT05144321Pregnant With Complication, Twin Pregnancy With Antenatal Problem

University Hospital, Montpellier

Observational

150

Montpellier

2021-11-01

Active, closed

A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma

NCT04712097Relapsed or Refractory Follicular Lymphoma

DrugsMosunetuzumab·Lenalidomide·Rituximab

Hoffmann-La Roche

Phase 3

478

Bayonne, Chambéry, Créteil, Lille, Marseille, Montpellier, Nantes, Nice

2021-10-27

Active, closed

A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

NCT04861259Atypical Hemolytic Uremic Syndrome

DrugCrovalimab

Hoffmann-La Roche

Phase 3

Montpellier, Paris

2021-10-22

Active, closed

Immunotherapy in MSI/dMMR Tumors in Perioperative Setting.

NCT04795661Localized Resectable Tumor, MSI/dMMR

DrugPembrolizumab

Centre Leon Berard

Phase 2

240

Amiens, Clermont-Ferrand, Dijon, Lille, Lyon, Marseille, Montpellier, Nice

2021-10-18

Active, closed

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

NCT05104866Breast Cancer

DrugsEribulin·Dato-DXd·Vinorelbine·Capecitabine

AstraZeneca

Phase 3

732

Bezannes, Bordeaux, Lille, Lyon, Montpellier, Plérin, Toulouse, Villejuif

2021-10-18

Active, closed

Study on an Investigational Yellow Fever Vaccine Compared With Stamaril in Adults in Europe and Asia

NCT05011123Yellow Fever

DrugYellow fever vaccine

Sanofi Pasteur, a Sanofi Company

Phase 2

690

Lyon, Montpellier, Nantes, Nîmes, Paris, Pierre-Bénite

2021-10-07

Active, closed

Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis

NCT04926818Multiple Sclerosis (MS)

DrugsSiponimod·Fingolimod·Ofatumumab

Novartis Pharmaceuticals

Phase 3

129

Le Kremlin-Bicêtre, Montpellier, Strasbourg

2021-10-05

Active, closed

A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

NCT04975308Breast Neoplasms, Neoplasm Metastasis

DrugsImlunestrant·Exemestane·Abemaciclib·Fulvestrant

Eli Lilly and Company

Phase 3

874

Strasbourg, La Chaussée-Saint-Victor, Besançon, Saint-Cloud, Montpellier, Le Mans, Bayonne, Paris

2021-10-04

Active, closed

In Vivo Clinical Investigation of the Safety and Performance of Dental Implants TBR® Bone Level

NCT04984486Edentulous

Sudimplant SAS - Groupe TBR

Observational

138

Montpellier

2021-09-27

Recruiting

Evaluation of the Impact of Case Manager Intervention on the 3-year Psychotic Episode Recurrence Rate in Patients Aged 16 to 30 Years With a First Psychotic Episode.

NCT05116514Psychotic Episode

Centre Hospitalier Universitaire de Nīmes

Not applicable

256

Toulouse, Clermont-Ferrand, Montpellier, Nice, Nîmes, Thuir

2021-09-27

Active, closed

Study of INBRX-109 in Conventional Chondrosarcoma

NCT04950075Conventional Chondrosarcoma

DrugINBRX-109

Inhibrx Biosciences, Inc

Phase 2

206

Bordeaux, Lille, Lyon, Marseille, Montpellier, Nice, Paris, Rennes

2021-09-23

Active, closed

In Vivo Clinical Investigation of the Safety and Performance of Dental Implants TBR® Tissue Level Z1

NCT04984499Edentulous Mouth

Sudimplant SAS - Groupe TBR

Observational

152

Montpellier

2021-09-23

Recruiting

Evolution of Intestinal Microbiota in Patients With Juvenile Spondylarthropathy According to Typology of Treatment

NCT04540432Spondylarthropathies

Centre Hospitalier Universitaire de Nīmes

Not applicable

Nîmes, Montpellier, Marseille, Toulouse

2021-09-22

Recruiting

Impact of Cardiac Coherence on Anxiety in Patients Operated on for a Peritoneal Carcinosis

NCT04024917Peritoneal Carcinomatosis, Pseudomyxoma Peritonei, Mesothelioma Peritoneum

Institut du Cancer de Montpellier - Val d'Aurelle

Not applicable

Montpellier

2021-09-21

Active, closed

A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

NCT04965493Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugsRiabni·Ruxience·Truxima·Pirtobrutinib

Loxo Oncology, Inc.

Phase 3

600

Le Mans, Montpellier, Morvan, Nantes, Paris, Pierre-Bénite, Politiers, Rennes

2021-09-20

Recruiting

Validation of the RADIAL Algorithm for Diagnosis of Autosomal Recessive Cerebellar Ataxia

NCT04261127Autosomal Recessive Cerebellar Ataxia

University Hospital, Strasbourg, France

Not applicable

400

Besançon, Dijon, Lille, Marseille, Montpellier, Nancy, Strasbourg, Toulouse

2021-09-20

Recruiting

A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

NCT04557462Primary IgA Nephropathy

DrugIptacopan

Novartis Pharmaceuticals

Phase 3

540

Marseille, Montpellier, Paris

2021-09-20

Active, closed

A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate

NCT04909801Rheumatoid Arthritis

DrugsAbatacept·Humira·Adalimumab·Methotrexate

Bristol-Myers Squibb

Phase 3

338

Montpellier, Rouen, Strasbourg, Toulouse

2021-09-15

Active, closed

Open-label, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection (MK-8591A-033)

NCT04776252HIV-1 Infection

DrugDOR/ISL

Merck Sharp & Dohme LLC

Phase 3

2,000

Nice, Dijon, Bordeaux, Toulouse, Rouen, Montpellier, Nantes, Tourcoing

2021-09-15

Recruiting

Intestine-lung Axis of Cystic Fibrosis Patients Treated With the Combination Elexacaftor/Tezacaftor/Ivacaftor

NCT05937815Cystic Fibrosis

University Hospital, Bordeaux

Not applicable

253

Bordeaux, Grenoble, Lille, Limoges, Lyon, Marseille, Montpellier, Nancy

2021-09-13

Recruiting

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

NCT05006716B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma

DrugTacabrutideg

BeOne Medicines

Phase 1/2

689

Bordeaux, ClermontFerrand, Créteil, Lille, Lyon, Marseille, Montpellier, Paris

2021-09-13

Recruiting

Professional Life After Breast Cancer: Feasibility of a Coaching Program for an Adapted Return to Work

NCT05056350Breast Cancer

Institut du Cancer de Montpellier - Val d'Aurelle

Not applicable

Montpellier

2021-09-13

Recruiting

Clinical Features Associated With Restless Legs Syndrome.

NCT05044520Restless Legs Syndrome

University Hospital, Montpellier

Observational

2,000

Montpellier

2021-09-01

Active, closed

A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)

NCT04961996Early Breast Cancer

DrugGiredestrant

Hoffmann-La Roche

Phase 3

4,170

Caen, Limoges, Montpellier, Argenteuil, Brest, Grenoble, La Roche-sur-Yon, Le Mans

2021-08-27

Active, closed

Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)

NCT04976634Neoplasm Malignant

DrugsBelzutifan·Lenvatinib·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 2

730

Rennes, Besançon, Brest, Montpellier, La Tronche, Avignon, Clichy

2021-08-18

By invitation

Selatogrel Outcome Study in Suspected Acute Myocardial Infarction

NCT04957719Acute Myocardial Infarction

Viatris Innovation GmbH

Phase 3

25,000

Pessac, Brest, Caen, La Roche-sur-Yon, Le Coudray, Marseille, Montpellier, Nîmes

2021-08-14

Active, closed

Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin

NCT04960709Muscle Invasive Bladder Cancer

DrugsEnfortumab Vedotin·Tremelimumab·Durvalumab

AstraZeneca

Phase 3

712

Amiens, Bayonne, Clermont-Ferrand, Lille, Lyon, Marseille, Montpellier, Nice

2021-08-05

Recruiting

Addition of Pembrolizumab to the Standard of Care Chemotherapy in Patient With SCCOHT

NCT04602377Small Cell Ovarian Carcinoma

DrugsKeytruda·Pembrolizumab

ARCAGY/ GINECO GROUP

Phase 2

Angers, Besançon, Bordeaux, Dijon, Lille, Limoges, Lyon, Montpellier

2021-08-04

Recruiting

A Study of 177Lu-FAP-2286 in Advanced Solid Tumors

NCT04939610Solid Tumor

Drug177Lu-FAP-2286

Novartis Pharmaceuticals

Phase 1/2

222

Montpellier, Bordeaux, Clermont-Ferrand, Marseille, Vandœuvre-lès-Nancy

2021-07-30

Recruiting

Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.

NCT04817618C3G

DrugIptacopan

Novartis Pharmaceuticals

Phase 3

Lille, Marseille, Montpellier, Paris

2021-07-28

Recruiting

Characterization of a Functional Test for Mediterranean Family Fever Screening - 2

NCT04478409Familial Mediterranean Fever, MEFV Gene Mutation

Hospices Civils de Lyon

Observational

160

Bron, Le Chesnay, Lyon, Montpellier, Nîmes, Paris, Pierre-Bénite

2021-07-21

Recruiting

Efficacy of Regorafenib Combined With Best Supportive Care as Maintenance Treatment in High Grade Bone Sarcomas Patients

NCT04698785Bone Sarcoma, Osteosarcoma

Centre Leon Berard

Phase 2

Besançon, Bordeaux, Dijon, Lille, Lyon, Marseille, Montpellier, Nantes

2021-07-21

Active, closed

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

NCT04956640Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Endometrial Neoplasms, Ovarian Neoplasms

DrugsOlomorasib·Erbitux·Cetuximab·Pemetrexed

Eli Lilly and Company

Phase 1/2

540

Bordeaux, Lyon, Montpellier, Toulouse, Villejuif

2021-07-19

Active, closed

A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases

NCT04554914Epstein-Barr Virus (EBV)-Associated Diseases, EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD), EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (EBV+ AID LPD), EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD)

DrugTabelecleucel

Pierre Fabre Medicament

Phase 2

190

Montpellier, Paris

2021-07-14

Active, closed

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs

NCT04908202Psoriatic Arthritis

DrugDeucravacitinib

Bristol-Myers Squibb

Phase 3

670

Chambray-lès-Tours, Montpellier, Paris

2021-07-13

Recruiting

Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs

NCT04613921Liver Diseases, Liver Cirrhosis, Acute-On-Chronic Liver Failure, Liver Transplant; Complications

European Foundation for Study of Chronic Liver Failure

Observational

3,000

Clichy, Créteil, Lyon, Montpellier, Paris, Rennes, Strasbourg, Tours

2021-07-08

Active, closed

Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

NCT04915755Neoplasms, Breast

DrugNiraparib

GlaxoSmithKline

Phase 3

Avignon, Bordeaux, Caen, Dijon, Marseille, Montpellier, Pierre-Bénite, Rouen

2021-06-28

Recruiting

WE-TRUST (Workflow Optimization to Reduce Time to Endovascular Reperfusion for Ultra-fast Stroke Treatment)

NCT04701684Stroke, Acute

Philips Clinical & Medical Affairs Global

Not applicable

594

Lyon, Montpellier, Paris

2021-06-23

Active, closed

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

NCT04895358Breast Neoplasms

DrugsLiposomal doxorubicin·Abraxane·Xeloda·Taxol

Merck Sharp & Dohme LLC

Phase 3

342

Lyon, Marseille, Caen, Besançon, Toulouse, Montpellier, Saint-Herblain, Angers

2021-06-18

Active, closed

Predictive Value of microRNA in Thyroid Cytologies of Undetermined Type

NCT04285476Thyroid Cancer

Institut du Cancer de Montpellier - Val d'Aurelle

Not applicable

Toulouse, Montpellier, Nîmes

2021-06-17

Recruiting

Sequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by Stereotactic MRI-guided Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

NCT04570943Locally Advanced Pancreatic Adenocarcinoma

Institut du Cancer de Montpellier - Val d'Aurelle

Phase 2

103

Marseille, Nîmes, Montpellier, Clichy, Dijon, Paris, Rennes, Villejuif

2021-06-16

Active, closed

An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

NCT04720157Prostatic Neoplasms

DrugsARDT·Illuccix·Lu-PSMA

Novartis Pharmaceuticals

Phase 3

1,140

Bordeaux, Clermont-Ferrand, Lyon, Montpellier, Nantes, Paris, Strasbourg, Vandœuvre-lès-Nancy

2021-06-09

Active, closed

A Clinical Study on Implants With TiUltra Technology and Associated Prosthetic Components

NCT04737421Marginal Bone Level Change

Nobel Biocare

Observational

1,000

Lyon, Montpellier, Paris

2021-05-26

Active, closed

A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

NCT04895241Lupus Erythematosus, Systemic

DrugLitifilimab

Biogen

Phase 3

548

Bordeaux, Montpellier, Clermont-Ferrand

2021-05-25

Active, closed

Value of the Laparoscopic Approach in the Surgical Management of Resectable Hepatocellular Carcinoma

NCT04791735Hepatocellular Carcinoma

Assistance Publique - Hôpitaux de Paris

Not applicable

252

Amiens, Besançon, Clichy, Créteil, Grenoble, Lille, Lyon, Montpellier

2021-05-21

Active, closed

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

NCT04704934Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma

DrugsRamucirumab·Trastuzumab deruxtecan·Paclitaxel

Daiichi Sankyo

Phase 3

490

Besançon, Brest, Lille, Lyon, Marseille, Montpellier, Paris, Saint-Priest-en-Jarez

2021-05-21

Active, closed

A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme

NCT04762069Glioblastoma Multiforme, Adult

DrugsCCNU·Lomustine

CNS Pharmaceuticals, Inc.

Phase 2

252

Lyon, Marseille, Montpellier, Paris, Saint-Herblain, Toulouse, Villejuif

2021-05-18

Recruiting

Diet Modification in pAtients With Luminal Early Breast Cancer Candidate for Primary Surgery

NCT04469296Breast Cancer, Surgery

Institut du Cancer de Montpellier - Val d'Aurelle

Not applicable

Montpellier

2021-05-18

Recruiting

Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer

NCT04965766Metastatic Breast Cancer, Advanced Breast Cancer

DrugPatritumab deruxtecan

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2

139

Dijon, Limoges, Lyon, Marseille, Montpellier, Nice, Paris, Saint-Herblain

2021-05-11

By invitation

Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM

NCT04848506Symptomatic Hypertrophic Cardiomyopathy (HCM)

DrugAficamten

Cytokinetics

Phase 2/3

900

Marseille, Montpellier, Nantes, Paris, Pessac, Rennes, Toulouse

2021-05-06

Active, closed

A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease

NCT04777331Parkinsons Disease

DrugPrasinezumab

Hoffmann-La Roche

Phase 2

586

Bordeaux, Bron, Clermont-Ferrand, Créteil, Grenoble, Limoges, Marseille, Montpellier

2021-05-05

Active, closed

A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab

NCT04770896Unresectable Hepatocellular Carcinoma

DrugsSorafenib·Tecentriq·Atezolizumab·Lenvatinib

Hoffmann-La Roche

Phase 3

557

Grenoble, Lille, Marseille, Montpellier, Nantes, Paris, Pessac, Rennes

2021-04-26

Active, closed

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

NCT04784715Breast Cancer; HER2-positive; Metastatic

DrugsPertuzumab·Trastuzumab deruxtecan·Trastuzumab

AstraZeneca

Phase 3

1,157

Avignon, Besançon, Bordeaux, Caen, Le Mans, Montpellier, Nice, Paris

2021-04-26

Active, closed

A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

NCT04527380Juvenile Psoriatic Arthritis, Enthesitis Related Arthritis

DrugsIxekizumab·Adalimumab

Eli Lilly and Company

Phase 3

101

Bron, Montpellier, Le Kremlin-Bicêtre, Poitiers, Paris

2021-04-13

Active, closed

Economic Evaluation of Prostatic Urethral Lift

NCT04726748Benign Prostatic Hyperplasia

University Hospital, Bordeaux

Observational

1,360

Lille, Montpellier, Paris, Pierre-Bénite, Talence, Tours

2021-04-08

Active, closed

Interactive Guidance Therapy With Video Feed-back of Parent and Child With Autism Spectrum Disorder

NCT04607616Autism Spectrum Disorders

Assistance Publique - Hôpitaux de Paris

Not applicable

Montpellier, Montreuil, Paris

2021-03-26

Active, closed

Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation

NCT04531046B-Cell Lymphoma Refractory, B-cell Lymphoma Recurrent

DrugsAxi-cel·Axicabtagene Ciloleucel

The Lymphoma Academic Research Organisation

Phase 2

Bordeaux, Clermont-Ferrand, Créteil, Dijon, Lille, Montpellier, Nantes, Paris

2021-03-10

Recruiting

Creation of a Register of Patients With Neonatal-onset Epileptic Encephalopathy

NCT04802135Epileptic Encephalopathy

Assistance Publique Hopitaux De Marseille

Observational

200

Angers, Bordeaux, Brest, Lille, Limoges, Lyon, Marseille, Montpellier

2021-03-06

Recruiting

Efficacy of Dorso-lateral Prefrontal Cortex Stimulation by tDCS in Motor Conversion Disorder Patients

NCT04097184Conversion Disorder

Centre Hospitalier Universitaire de Nīmes

Not applicable

Nîmes, Montpellier, Lyon, Nantes, Toulouse, Paris

2021-03-05

Recruiting

A Clinical Study to Assess Safety, Efficacy and Pharmacodynamic Profile of GNT0004 in Duchenne Muscular Dystrophy

NCT07856329Duchene Muscular Dystrophy

Genethon

Phase 2/3

Bordeaux, Brest, Bron, Lille, Montpellier, Paris, Strasbourg

2021-03-01

Active, closed

Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment

NCT04647526Metastatic Castration-Resistant Prostate Cancer

DrugsAbiraterone·Enzalutamide

POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company

Phase 3

455

Clermont-Ferrand, Lille, Lyon, Marseille, Montpellier, Paris

2021-02-25

Recruiting

LVAD Versus GDMT in Ambulatory Advanced Heart Failure Patients

NCT04768322End-stage Heart Failure

Hospices Civils de Lyon

Not applicable

Besançon, Bron, Caen, La Tronche, Montpellier, Rouen, Tours, Vandœuvre-lès-Nancy

2021-02-24

Active, closed

A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

NCT04408638Diffuse Large B-cell Lymphoma

DrugsRituxumab·Glofitamab·Tocilizumab·Obinutuzumab

Hoffmann-La Roche

Phase 3

270

Bordeaux, Créteil, Lille, Montpellier, Pierre-Bénite, Rennes

2021-02-23

Recruiting

Early Detection of Prostate Cancer

NCT04556916Prostate Cancer

University Hospital, Montpellier

Not applicable

320

Montpellier, Nîmes

2021-02-19

Active, closed

Liquid Biopsies and IMAging for Improved Cancer Care

NCT04224779Rectal Cancer

DrugBiological collection

Institut du Cancer de Montpellier - Val d'Aurelle

Not applicable

Montpellier

2021-02-18

Recruiting

Evaluation of the Efficacy of a Physical Therapy-yoga-patient Educational Program for Breast Cancer Patients With Pain Due to Hormonal Therapy Treatment.

NCT04457895Breast Cancer

Institut du Cancer de Montpellier - Val d'Aurelle

Not applicable

108

Libourne, Montpellier, Nîmes, Vandœuvre-lès-Nancy, Bordeaux, Tosse, Angers

2021-02-11

Recruiting

Impact of Neoadjuvant Hormonal Therapy on the Surgical Management of Extensive Ductal Carcinomas in Situ

NCT04666961Ductal Carcinoma in Situ, Extensive Disease, Mastectomy

DrugTamoxifen

Institut Cancerologie de l'Ouest

Phase 2

262

Angers, Bordeaux, Montpellier, Nice, Paris, Saint-Herblain, Toulouse

2021-02-03

Recruiting

Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients

NCT03127267Amyotrophic Lateral Sclerosis

DrugsMasitinib·Riluzole

AB Science

Phase 3

495

Angers, Bordeaux, Bron, Clermont-Ferrand, Lille, Limoges, Marseille, Montpellier

2021-02-02

Recruiting

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT04634552Hematological Malignancies

DrugTalquetamab

Janssen Research & Development, LLC

Phase 2

510

Créteil, Lyon, Montpellier, Nantes, Pessac, Toulouse

2021-02-01

Active, closed

A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)

NCT04624659Sickle Cell Disease

DrugEtavopivat

Forma Therapeutics, Inc.

Phase 3

450

Créteil, Lyon, Montpellier, Mulhouse, Paris, Saint-Denis

2021-01-29

Active, closed

A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease

NCT04711252ER-Positive HER2-Negative Breast Cancer

DrugsCamizestrant·Anastrozole·Palbociclib

AstraZeneca

Phase 3

1,371

Besançon, Bordeaux, Brest, Caen, Dijon, Le Mans, Lille, Montpellier

2021-01-28

Recruiting

Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma

NCT04031677Retroperitoneal Sarcoma, Liposarcoma, Leiomyosarcoma

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3

250

Lyon, Montpellier, Paris, Strasbourg, Villejuif

2021-01-20

Recruiting

Evaluation of the PICO® Negative Pressure Dressing System on the Fibula Free Flap Donor Site's Skin Graft.

NCT04628416Carcinomatous Resections, Violent Trauma

University Hospital, Montpellier

Not applicable

112

Montpellier

2021-01-18

Recruiting

Discovery of Soluble Biomarkers for Pancreatic Cancer Using Innovative All-Patient Inclusive Methodology

NCT04370574Pancreatic Neoplasms

University Hospital, Montpellier

Observational

200

Montpellier

2021-01-14

Active, closed

Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)

NCT04634877Endometrial Neoplasms

DrugsDocetaxel·Keytruda·Paclitaxel·Cisplatin

Merck Sharp & Dohme LLC

Phase 3

990

Vandœuvre-lès-Nancy, Nice, Caen, Plérin, Besançon, Bordeaux, Toulouse, Montpellier

2021-01-10

Active, closed

A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation

NCT04625270Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer

DrugsAvutometinib (VS-6766) and defactinib·Avutometinib

Verastem, Inc.

Phase 2

225

Besançon, Lyon, Montpellier, Paris

2020-12-21

Active, closed

A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy

NCT04640623Urinary Bladder Neoplasms

DrugsTAR-200·Cetrelimab

Janssen Research & Development, LLC

Phase 2

220

Bordeaux, Grenoble, Hyères, Limoges, Lyon, Marseille, Montpellier, Nîmes

2020-12-18

Active, closed

GYNecological Cancers Treated with NETrin MAbs in Combination with Chemotherapy and /or Pembrolizumab

NCT04652076Endometrial Carcinoma, Cervix Carcinoma

DrugsNP137·Keytruda·Paclitaxel·Carboplatin

NETRIS Pharma

Phase 1/2

240

Besançon, Bordeaux, Caen, Dijon, Lille, Lyon, Marseille, Montpellier

2020-12-14

Recruiting

Predictive Toxicity Test Linked to Radiotherapy After Mastectomy and Immediate Implant Reconstruction

NCT04342546Breast Cancer, Capsular Contracture Associated With Breast Implant

Institut du Cancer de Montpellier - Val d'Aurelle

Not applicable

250

Dijon, Lille, Lyon, Marseille, Montpellier, Nice, Paris, Saint-Herblain

2020-12-11

Active, closed

Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome

NCT04623541Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome, Treatment-naïve High Risk Chronic Lymphocytic Leukemia

DrugsEpcoritamab·Pirtobrutinib·Lenalidomide·Venetoclax

Genmab

Phase 1/2

194

Montpellier, Pessac, Vandœuvre-lès-Nancy, Paris, Nantes, Clermont-Ferrand

2020-11-25

Recruiting

Pilot Study for Thyroid Surgery by Preoperative Video Support and Personalized and Secure Web Platform

NCT04571736Thyroid

University Hospital, Montpellier

Not applicable

220

Montpellier

2020-11-18

Active, closed

Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer

NCT04592913Gastrointestinal Neoplasms, Esophagogastric Junction

DrugDurvalumab

AstraZeneca

Phase 3

957

Avignon, Besançon, Brest, Dijon, Lyon, Montpellier, Nantes, Nice

2020-11-17

Recruiting

Hematological Anomalies in Children With Rasopathy

NCT04286360RAS Mutation

Assistance Publique - Hôpitaux de Paris

Observational

300

Angers, Caen, Lille, Lyon, Marseille, Montpellier, Nantes, Paris

2020-11-11

Active, closed

Safety and Clinical Performance of a Biological Matrix Used in Abdominal Wall Reconstruction

NCT04580511Abdominal Wall Defect, Abdominal Wall Injury, Abdominal Hernia

Meccellis Biotech

Observational

Caen, La Rochelle, Montpellier, Nantes

2020-11-04

Recruiting

The AFteR Registry - Follow-up Study to Monitor the Efficacy and Safety of the Occlutech AFR in Heart Failure Patients

NCT04405583Heart Failure

Occlutech International AB

Observational

150

Besançon, Bourdeaux, Lyon, Montpellier, Toulouse

2020-10-28

Active, closed

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis

NCT04544449Multiple Sclerosis, Primary Progressive

DrugsFenebrutinib·Ocrelizumab

Hoffmann-La Roche

Phase 3

985

Bordeaux, Bron, Montpellier, Nantes, Nice, Strasbourg

2020-10-26

Active, closed

Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC

NCT04550260Esophageal Squamous Cell Carcinoma

DrugsFluorouracil·Durvalumab·Capecitabine·Cisplatin

AstraZeneca

Phase 3

640

Besançon, Lille, Lyon, Montpellier, Reims, Rouen, Strasbourg, Villejuif

2020-10-19

Recruiting

Interest of Peri Operative CHemotherapy In Patients With CINSARC High-risk Localized Soft Tissue Sarcoma

NCT04307277Soft Tissue Sarcoma

Institut Claudius Regaud

Phase 3

600

Besançon, Caen, Clermont-Ferrand, Dijon, Limoges, Lyon, Marseille, Montpellier

2020-10-09

Active, closed

A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)

NCT04546009Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

DrugsGiredestrant·Palbociclib·Letrozole

Hoffmann-La Roche

Phase 3

992

Angers, Bayonne, La Roche-sur-Yon, Montpellier, Poitiers, Reims, Rennes, Saint-Priest-en-Jarez

2020-10-09

Active, closed

A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)

NCT04529772Diffuse Large B-Cell Lymphoma

DrugsAcalabrutinib·Vincristine·Doxorubicin·Prednisone

Acerta Pharma BV

Phase 3

611

Brest, Caen, Marseille, Montpellier, Nantes, Pessac, Pierre-Bénite, Rennes

2020-10-08

Active, closed

Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer

NCT04590963Squamous Cell Carcinoma of the Head and Neck

DrugsMonalizumab·Erbitux·Cetuximab

AstraZeneca

Phase 3

370

Avignon, Bordeaux, Clermont-Ferrand, Dijon, Lyon, Marseille, Montpellier, Strasbourg

2020-10-02

Active, closed

Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)

NCT04524611Crohn's Disease (CD)

DrugsSkyrizi·Risankizumab·Ustekinumab

AbbVie

Phase 3

527

Nice, Clermont, Marseille, Pessac, Montpellier, La Tronche, Reims, Vandœuvre-lès-Nancy

2020-09-30

Recruiting

Subcutaneous Injections of ASC to Heal Digital Ulcers in Patients With Scleroderma.

NCT04356755Systemic Sclerosis

DrugAdMSC

University Hospital, Toulouse

Phase 2

Grenoble, Lille, Marseille, Montpellier, Nantes, Poitiers, Toulouse

2020-09-22

Recruiting

SHame prOpensity in bOrderline Personality Disorder

NCT03994510Borderline Personality Disorder

University Hospital, Montpellier

Not applicable

688

Montpellier

2020-09-18

Recruiting

Intensive Intraperitoneal Therapy in Advanced Ovarian Cancer

NCT04282356Ovarian Cancer, Intraperitoneal Chemotherapy

Institut du Cancer de Montpellier - Val d'Aurelle

Phase 2

Montpellier

2020-09-15

Recruiting

Pediatric Perioperative Satisfaction Questionnaire

NCT04608968Perioperative, Children, Satisfaction

University Hospital, Montpellier

Observational

600

Montpellier, Bordeaux, Grenoble, Nîmes, Reims, Toulouse

2020-09-01

Active, closed

Efficacy and Safety of L19TNF in Previously Treated Patients with Advanced Stage or Metastatic Soft-tissue Sarcoma

NCT04733183Soft Tissue Sarcoma

DrugsOnfekafusp alfa·Dacarbazine

Philogen S.p.A.

Phase 2

Besançon, Bordeaux, Clermont-Ferrand, Lyon, Marseille, Montpellier, Toulouse, Villejuif

2020-08-28

Recruiting

Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas

NCT04224064Liposarcoma, Atypical Lipomatous Tumor

Institut du Cancer de Montpellier - Val d'Aurelle

Not applicable

158

Montpellier

2020-08-26

Recruiting

Acid-Sensing Ion Channel and Migraine Disease Proof of Concept Study on the Efficacy of Amiloride in the Prophylaxis of Migraine Aura

NCT04063540Migraine With Aura

DrugAmiloride

Centre Hospitalier Universitaire de Nice

Phase 2

Bron, Clermont-Ferrand, Marly, Montpellier, Nice

2020-08-11

Active, closed

Comparison of an Inhaled Sedation Strategy to an Intravenous Sedation Strategy in Intensive Care Unit Patients Treated With Invasive Mechanical Ventilation

NCT04341350Prevention of Delirium

DrugsIsoflurane·Propofol

University Hospital, Brest

Phase 3

250

Bourges, Brest, Corbeil-Essonnes, Le Mans, Lorient, Melun, Montpellier, Morlaix

2020-08-06

Active, closed

A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)

NCT04245839Lymphoma, Non-Hodgkin

DrugsLiso-cel·Fludarabine·Cyclophosphamide

Celgene

Phase 2

276

Lille, Montpellier, Paris, Pierre-Bénite, Rennes, Toulouse

2020-07-14

Active, closed

Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency

NCT04493853Hormone-Sensitive Prostate Cancer

DrugsZytiga·Capivasertib·Abiraterone acetate

AstraZeneca

Phase 3

1,012

Besançon, Bordeaux, Marseille, Montpellier, Nice, Paris, Pierre-Bénite, Quimper

2020-07-13

Recruiting

OP2C : Prialt® Observatory in Clinical Practice

NCT04321408Refractory Pain

DrugZiconotide

Institut Cancerologie de l'Ouest

Observational

300

Angers, La Roche-sur-Yon, Lyon, Montpellier, Nantes, Nice, Saint-Cloud, Suresnes

2020-07-10

Active, closed

A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

NCT04232553Crohn's Disease

DrugMirikizumab

Eli Lilly and Company

Phase 3

996

Montpellier, Vandœuvre-lès-Nancy, Poitiers

2020-06-22

Recruiting

Constitution of a Clinical, Neurophysiological and Biological Cohort for Chronic Sleep Disorders Responsible of Hypersomnolence

NCT03998020Somnolence Disorder, Excessive

University Hospital, Montpellier

Not applicable

5,000

Montpellier

2020-06-16

Active, closed

A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma

NCT04181827Multiple Myeloma

DrugsCilta-cel·Pomalidomide·Bortezomib·Daratumumab

Janssen Research & Development, LLC

Phase 3

419

Lille, Lyon, Montpellier, Nantes, Paris, Poitiers, Toulouse

2020-06-12

Recruiting

Stereotaxic Body Irradiation of Oligometastase in Sarcoma (Stereosarc)

NCT03548428Sarcoma, Radiosurgery

DrugAtezolizumab

Centre Antoine Lacassagne

Phase 2

103

Bordeaux, Caen, Dijon, Lille, Lyon, Marseille, Montpellier, Nice

2020-06-04

Recruiting

Role of the Environment and Endocrine Disruptors in Child Cryptorchidism

NCT04342026Cryptorchidism

University Hospital, Montpellier

Observational

1,452

Montpellier

2020-04-16

Active, closed

Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

NCT04162210Multiple Myeloma

DrugsBelantamab mafodotin·Dexamethasone

GlaxoSmithKline

Phase 3

325

Le Mans, Montpellier, Poitiers

2020-04-02

Recruiting

Collection of Biological Samples From Patients Treated With CAR-T Cells for Hematological Malignancies

NCT04290000Lymphoma and Acute Lymphoblastic Leukemia

University Hospital, Montpellier

Observational

300

Montpellier

2020-03-27

Recruiting

Study of BDNF Pathway Biomarkers in the Cerebrospinal Fluid in Patients With Huntington's Disease

NCT04012411Huntington Disease

University Hospital, Montpellier

Not applicable

135

Montpellier

2020-03-03

Recruiting

Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas

NCT04055220Bone Sarcoma, Osteosarcoma, Ewing Sarcoma, Chondrosarcoma

DrugRegorafenib

Centre Leon Berard

Not applicable

168

Besançon, Bordeaux, Lille, Lyon, Marseille, Montpellier, Paris, Poitiers

2020-03-03

Active, closed

Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)

NCT04199689Papillomavirus Infections

DrugNonavalent HPV vaccine

Merck Sharp & Dohme LLC

Phase 3

6,033

Dijon, Montpellier, Rennes, Nantes, Paris

2020-02-27

Active, closed

Monitoring to the Evolution of Motor Function in SMA Type II Adults Patients Treated With SPINRAZA®

NCT04159987Spinal Muscular Atrophy

Centre Hospitalier Universitaire de Nice

Not applicable

Lyon, Lille, Montpellier, Toulouse, Marseille, Nice, Paris

2020-02-25

Active, closed

A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

NCT04194944Non-Small Cell Lung Cancer

DrugsSelpercatinib·Pemetrexed·Cisplatin·Carboplatin

Eli Lilly and Company

Phase 3

261

Lyon, Marseille, Montpellier, La Tronche, Clermont-Ferrand, Paris

2020-02-17

Recruiting

APACHE Cohort (A Psoriatic Arthritis CoHort)

NCT03768271Cohort Study, Psoriatic Arthritis (PsA), Recent Peripheral Arthritis

Assistance Publique - Hôpitaux de Paris

Observational

425

Créteil, Montpellier, Paris

2020-02-12

Recruiting

Improving Theempowerment in Patients With Severe Breast Fibrosis Radio-induced Treated by Pravastatin : Benefit of e-PROs (Electronic " Patient Reported Outcome ") on Breast-related Quality of Life

NCT04356209Breast Cancer

DrugPravastatin

Institut du Cancer de Montpellier - Val d'Aurelle

Phase 2

105

Montpellier

2020-01-31

Active, closed

A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension

NCT04175600Hypertension, Pulmonary

DrugSelexipag

Actelion

Phase 3

138

Lille, Marseille, Montpellier, Paris, Pessac, Toulouse

2020-01-16

Recruiting

Determination of Microbiological Factors Associated With Poor Response to Neoadjuvant Treatment in Rectal Cancers

NCT04103567Rectal Cancer

Institut du Cancer de Montpellier - Val d'Aurelle

Not applicable

220

Montpellier, Clermont-Ferrand

2020-01-14

Recruiting

Assessment of Complication Risk Factors in a French National Cohort of Asplenic Patients

NCT04199403Asplenia

Poitiers University Hospital

Observational

6,000

Angoulême, Argenteuil, Béthune, Chartres, Lille, Montpellier, Nantes, Poitiers

2020-01-09

Active, closed

Combined Apalutamide, Radiotherapy, and LHRH Agonist in Prostate Cancer Patients After Prostatectomy

NCT04181203Prostate Cancer

DrugsLhrha·Leuprolide·Goserelin·Apalutamide

UNICANCER

Phase 3

490

Albi, Angers, Bordeau, Dijon, Le Puy-en-Velay, Lille, Montpellier, Nice

2020-01-09

Active, closed

Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET

NCT03972488Gastro-enteropancreatic Neuroendocrine Tumor

DrugsOctreotide LAR·Lutathera

Advanced Accelerator Applications

Phase 3

226

Clichy, Lyon, Montpellier, Nantes, Villejuif

2020-01-08

Active, closed

A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer

NCT04077099NSCLC

Regeneron Pharmaceuticals

Phase 1/2

Rennes, Bordeaux, Caen, Grenoble, Montpellier

2020-01-07

Active, closed

Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

NCT03772028Ovarian Cancer

DrugCisplatin

The Netherlands Cancer Institute

Phase 3

538

Besançon, Bordeaux, Lille, Lyon, Montpellier, Nantes, Paris, Strasbourg

2020-01-01

Recruiting

Natural History of Duchenne Muscular Dystrophy

NCT03882827Duchenne Muscular Dystrophy

Genethon

Observational

220

Bordeaux, Brest, Bron, Lille, Marseille, Montpellier, Paris, Strasbourg

2019-12-19

Recruiting

Von Willebrand Factor Point-of-care Testing to Improve Minimally Invasive TAVI Outcomes

NCT03728049Aortic Valve Stenosis, Aortic Valve Insufficiency

University Hospital, Lille

Not applicable

944

Clermont-Ferrand, Lille, Montpellier, Nîmes, Paris, Pessac, Rennes, Strasbourg

2019-12-18

Recruiting

Development of a Clinical and Biological Database in Peritoneal Carcinosis (BCB CARCINOSE)

NCT04221464Cancer, Peritoneal Carcinosis

DrugBiological collection

Institut du Cancer de Montpellier - Val d'Aurelle

Not applicable

600

Montpellier

2019-11-25

Active, closed

A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer

NCT04025879Carcinoma, Non-Small-Cell Lung

DrugsOpdivo·Pemetrexed·Docetaxel·Nivolumab

Bristol-Myers Squibb

Phase 3

461

Besançon, La Tronche, Montpellier, Paris, Rennes, Rouen

2019-11-05

Active, closed

Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.

NCT04157348Eosinophilic Granulomatous Vasculitis

DrugsBenralizumab·Mepolizumab

AstraZeneca

Phase 3

140

Dijon, Marseille, Montpellier, Nantes, Paris, Suresnes, Toulouse

2019-10-29

Recruiting

Clinico-biological Database in Patients Treated With Metabolic Radiotherapy in the Nuclear Medicine Department

NCT04104529Thyroid Cancer, Prostate Cancer, Neuroendocrine Tumors, SSTR Positive Tumors

Institut du Cancer de Montpellier - Val d'Aurelle

Not applicable

350

Bordeaux, Marseille, Montpellier, Toulouse

2019-10-28

Recruiting

A Study to Test GlaxoSmithKline's (GSK) Candidate Vaccine-GSK1437173A for Prevention of Shingles in Children With Kidney Transplant

NCT04006808Herpes Zoster

GlaxoSmithKline

Phase 1/2

184

Bordeaux, Lille, Marseille, Montpellier, Nantes, Paris, Toulouse

2019-10-25

Recruiting

Study of Genetic Determinants in Alcoholic Hepatitis and Establishment of a Multicenter Prospective Cohort of Patients With Alcoholic Liver Disease

NCT04106518Alcoholic Liver Disease, Severe Alcoholic Hepatitis, Alcoholic Cirrhosis

University Hospital, Lille

Observational

447

Angers, Besançon, Bondy, Caen, La Tronche, Lille, Marseille, Montpellier

2019-10-23

Active, closed

Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma.

NCT04006262Localized Oesogastric Adenocarcimona, MSI and or dMMR

DrugsYervoy·Ipilimumab·Opdivo·Nivolumab

GERCOR - Multidisciplinary Oncology Cooperative Group

Phase 2

Besançon, Créteil, Levallois-Perret, Lille, Lyon, Montpellier, Nantes, Paris

2019-10-23

Recruiting

Performing a Low-dose, Whole-body Angiography as the First Element of an Imaging Assessment Following Stroke / TIA

NCT02662751Stroke, Ischemic Attack, Transient

Centre Hospitalier Universitaire de Nīmes

Not applicable

260

Montpellier, Nîmes

2019-10-21

Active, closed

A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis

NCT03958877Multiple Sclerosis, Relapsing-Remitting

DrugsPlegridy·Avonex

Biogen

Phase 3

152

Strasbourg, Toulouse, Montpellier, Lille, Le Kremlin-Bicêtre

2019-10-18

Recruiting

Erectile Dysfunction in Good Prognosis Prostate Cancer : Comparison Between Brachytherapy and Stereotactic Body Radiotherapy

NCT03830788Prostate Cancer

Center Eugene Marquis

Not applicable

240

Albi, Angers, Bordeaux, Dijon, La Garenne-Colombes, Levallois-Perret, Lyon, Montpellier

2019-10-04

Recruiting

Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN

NCT03955445C3 Glomerulopathy, Immune-complex-membranoproliferative Glomerulonephritis

DrugIptacopan

Novartis Pharmaceuticals

Phase 3

225

Montpellier, Paris, Toulouse

2019-10-03

Active, closed

MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas

NCT03697512Marginal Zone Lymphoma, Nodal Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma

DrugsIbrutinib·Rituximab

International Extranodal Lymphoma Study Group (IELSG)

Phase 2

175

Tours, Montpellier, Clermont-Ferrand, Rennes, Bordeaux, Caen, Dijon, La Tronche

2019-09-27

Active, closed

A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis

NCT04033445Ulcerative Colitis

DrugGuselkumab

Janssen Research & Development, LLC

Phase 2/3

1,064

Caen, Clichy, Lille, Montpellier, Nice, Paris, Pessac, Pierre-Bénite

2019-09-26

Active, closed

An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis

NCT03950232Ulcerative Colitis

DrugEtrasimod

Pfizer

Phase 3

896

Amiens, Grenoble, Montpellier, Nantes, Nice, Toulouse

2019-09-05

Active, closed

A Post-market Clinical Follow up of the Genio® System for the Treatment of Obstructive Sleep Apnea in Adults

NCT04031040Obstructive Sleep Apnea

Nyxoah S.A.

Not applicable

110

Angers, Créteil, Lille, Montpellier, Paris, Rennes, Toulouse

2019-09-01

Active, closed

Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.

NCT04053322ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer, a Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status

DrugsOlaparib·Fulvestrant·Durvalumab

UNICANCER

Phase 2

172

Montpellier, Rouen

2019-08-26

Active, closed

A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

NCT04077723Lymphoma, Non-Hodgkin

DrugsGlofitamab·Tocilizumab·Obinutuzumab

Hoffmann-La Roche

Phase 1/2

498

Lille, Montpellier, Pierre-Bénite, Rennes

2019-08-13

Active, closed

A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)

NCT04008030Metastatic Colorectal Cancer

DrugsFluorouracil·Leucovorin·Ipilimumab·Irinotecan

Bristol-Myers Squibb

Phase 3

839

Limoges, Lille, Bayonne, Besançon, Lyon, Marseille, Montpellier, Nantes

2019-08-05

Active, closed

Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)

NCT03924895Urinary Bladder Cancer, Muscle-invasive

DrugsEnfortumab Vedotin·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

595

Marseille, Dijon, Caen, Besançon, Nîmes, Bordeaux, Toulouse, Montpellier

2019-07-24

Recruiting

A Prospective Cohort Study of Patients Suffering From Hand Osteoarthritis Symptoms

NCT03650673Hand Osteoarthritis

University Hospital, Montpellier

Not applicable

150

Montpellier

2019-07-15

Active, closed

Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)

NCT03974022Non-Small Cell Lung Cancer

DrugSunvozertinib

Dizal Pharmaceuticals

Phase 1/2

315

Angers, Bron, Dijon, Hellemmes-Lille, Marseille, Montpellier, Paris, Poitiers

2019-07-09

Active, closed

A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)

NCT04035486Non-Small Cell Lung Cancer

DrugsPemetrexed/Cisplatin·Pemetrexed/Carboplatin·Osimertinib

AstraZeneca

Phase 3

587

Bordeaux, Lyon, Montpellier, Villejuif

2019-07-02

Active, closed

Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC

NCT03997123Triple Negative Breast Neoplasms

DrugsCapivasertib·Paclitaxel

AstraZeneca

Phase 3

923

Brest, Lyon, Marseille, Montpellier, Nice, Paris, Saint-Herblain, Villejuif

2019-06-25

Active, closed

Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

NCT03937219Renal Cell Carcinoma

DrugsCabozantinib·Yervoy·Ipilimumab·Opdivo

Exelixis

Phase 3

855

Bordeaux, Le Mans, Lyon, Montpellier, Nice, Paris, Reims, Rennes

2019-06-25

Active, closed

Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD)

NCT03992417Dermatitis Atopic

DrugDupilumab

Sanofi

Observational

955

2019-06-11

Active, closed

Evaluation of the Safety and Efficacy of TLD in Patients with COPD

NCT03639051COPD

Nuvaira, Inc.

Not applicable

464

Grenoble, Toulouse, Brest, Montpellier, Nice, Paris, Reims, Strasbourg

2019-05-23

Recruiting

Clinical Database of Safe Personalized Adjuvant Breast Radiotherapy Based on Individual Radiosensitivity

NCT04282122Breast Cancer

Institut du Cancer de Montpellier - Val d'Aurelle

Observational

500

Montpellier

2019-05-23

Active, closed

A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

NCT03930953Lymphoma, Non-Hodgkin

DrugsValemetostat·Tafasitamab·Golcadomide·Obinutuzumab

Celgene

Phase 1/2

438

Bordeaux, Créteil, Lille, Montpellier, Paris, Pierre-Bénite, Rouen, Toulouse

2019-05-20

Recruiting

Prospective Monocentric Clinical-biological Database

NCT04136132Pancreatic Cancer

Institut du Cancer de Montpellier - Val d'Aurelle

Not applicable

120

Montpellier

2019-05-15

Active, closed

Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer (CHIPPI)

NCT03842982Ovary Neoplasms, Ovarian Cancer, Ovarian Carcinoma

DrugHipec

Centre Oscar Lambret

Phase 3

362

Angers, Bordeaux, Caen, Clermont-Ferrand, Lille, Marseille, Montpellier, Paris

2019-05-03

Active, closed

Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)

NCT03875235Biliary Tract Neoplasms

DrugDurvalumab

AstraZeneca

Phase 3

810

Clichy, Dijon, Montpellier, Nice, Paris, Pessac, Poitiers

2019-04-16

Active, closed

IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome

NCT03744390Myelodysplastic Syndromes, Leukemia Acute Myeloid

DrugEnasidenib

Groupe Francophone des Myelodysplasies

Phase 2

Versailles, Montpellier, Angers, Argenteuil, Bayonne, Bordeaux, Caen, Créteil

2019-04-02

Active, closed

Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients

NCT03829462Metastatic Colorectal Cancer (mCRC)

DrugsRegorafenib·Irinotecan

Institut du Cancer de Montpellier - Val d'Aurelle

Phase 3

377

Nice, Caen, Rennes, Reims, Perpignan, Lyon, Villejuif, Montpellier

2019-03-28

Active, closed

A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis

NCT03900429NASH - Nonalcoholic Steatohepatitis

DrugResmetirom

Madrigal Pharmaceuticals, Inc.

Phase 3

1,759

Strasbourg, Lyon, Clermont-Ferrand, Rennes, Besançon, Lille, Montpellier, Limoges

2019-03-28

Active, closed

A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease

NCT03887455Early Alzheimer's Disease

DrugLecanemab

Eisai Inc.

Phase 3

1,906

Marseille, Montpellier, Nantes, Paris, Toulouse, Bron, Strasbourg

2019-03-27

Active, closed

Prostate Cancer With OligometaSTatic Relapse: Combining Stereotactic Ablative Radiotherapy and Durvalumab (MEDI4736)

NCT03795207Node; Prostate, Bone Metastases, Prostate Cancer Patients

Institut Cancerologie de l'Ouest

Phase 2

Bordeaux, Brest, Dijon, Lille, Lorient, Lyon, Montpellier, Pierre-Bénite

2019-03-21

Active, closed

Efficacy of an Oral Immunomodulatory Nutrient on Survival During Postoperative Concomitant Chemoradiotherapy in Head and Neck Cancer

NCT04001543Head and Neck Squamous Cell Carcinoma

Institut du Cancer de Montpellier - Val d'Aurelle

Not applicable

Lyon, Montpellier

2019-03-14

Active, closed

Stereotactic Body Radiation Therapy (SBRT) Efficiency and Toxicity in Liver Cancer

NCT03408665Liver Cancer, Liver Metastases

Centre Oscar Lambret

Not applicable

280

Lille, Dechy, Montpellier, Sarcelles, Strasbourg, Vandœuvre-lès-Nancy, Villejuif

2019-03-13

Active, closed

Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL

NCT03836261Chronic Lymphocytic Leukemia

DrugsAcalabrutinib·Venclexta·Obinutuzumab·Venetoclax

Acerta Pharma BV

Phase 3

984

Montpellier, Paris, Rennes, Rouen, Toulouse, Villejuif

2019-02-25

Active, closed

Efficacy of Intradiscal Injection of BM-MSC in Subjects With Chronic Low Back Pain (LBP) Due to Lumbar Degenerative Disc Disease (DDD) Unresponsive

NCT03737461Recurrent Low Back Pain, Degenerative Disc Disease (DDD)

University Hospital, Montpellier

Phase 2/3

113

Montpellier, Nantes, Paris

2019-02-18

Recruiting

Benefit of Intensified Peri-operative Chemotherapy Within High-risk CINSARC Patients With Resectable Soft-tissue Sarcomas

NCT03805022Non-metastatic Soft-tissue Sarcoma, Resectable

DrugsDacarbazine·Ifosfamide·Doxorubicin

Institut Bergonié

Phase 3

351

Bordeaux, Dijon, Limoges, Lyon, Marseille, Montpellier, Saint-Herblain, Strasbourg

2019-02-14

Active, closed

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer

NCT03748641Castration-Resistant Prostatic Cancer

DrugsAbiraterone acetate·Niraparib·Prednisone

Janssen Research & Development, LLC

Phase 3

765

Besançon, Bordeaux, Clermont-Ferrand, Lyon, Montpellier, Nancy, Nice, Paris

2019-01-25

Active, closed

Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

NCT03650114Relapsing Multiple Sclerosis

Drugs13-valent pneumococcal conjugate vaccine·23-valent pneumococcal polysaccharide vaccine·Ofatumumab

Novartis Pharmaceuticals

Phase 3

1,882

Lille, Montpellier, Nantes, Nice, Nîmes, Paris, Strasbourg

2018-12-28

Active, closed

Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

NCT03725059Breast Cancer

DrugsEpirubicin·Adriamycin·Cytoxan·Taxol

Merck Sharp & Dohme LLC

Phase 3

1,240

Caen, Dijon, Toulouse, Lille, Saint-Cloud, Montpellier, Metz, Avignon

2018-12-27

Active, closed

Atezolizumab After Chemo-radiotherapy for MIBC Patients Not Eligible for Radical Cystectomy

NCT03697850Bladder Cancer

DrugAtezolizumab

UNICANCER

Phase 2

Bordeaux, Clermont-Ferrand, Dijon, Lille, Montpellier, Mougins, Nice, Paris

2018-12-14

Active, closed

A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma

NCT03778957Hepatocellular Carcinoma

DrugsAvastin·Durvalumab·Bevacizumab

AstraZeneca

Phase 3

724

Bobigny, Clichy, Grenoble, Montpellier, Nice, Paris, Pessac, Toulouse

2018-11-30

Active, closed

A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer

NCT03706365Prostate Cancer

DrugsAbiraterone acetate·Abemaciclib·Prednisone

Eli Lilly and Company

Phase 2/3

393

Lyon, Montpellier, Le Mans, La Roche-sur-Yon, Bordeaux, Créteil

2018-11-26

Active, closed

Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC

NCT03732677Muscle Invasive Bladder Cancer

DrugsDurvalumab·Gemcitabine·Cisplatin

AstraZeneca

Phase 3

1,063

Angers, Dijon, Grenoble, Montpellier, Nîmes, Pierre-Bénite, Poitiers, Rouen

2018-11-16

Active, closed

Efficacy of Repeat Stereotactic Radiation in Patients With Intraprostatic Tumor Recurrence

NCT03438552Local Recurrence of Malignant Tumor of Prostate

UNICANCER

Not applicable

Caen, Clermont-Ferrand, Dijon, Lille, Lyon, Montpellier, Paris, Rennes

2018-10-18

Active, closed

Study Impact on Outcome of Eltrombopag in Elderly Patients with Acute Myeloid Leukemia Receiving Induction Chemotherapy

NCT03603795Acute Myeloid Leukemia

DrugEltrombopag

French Innovative Leukemia Organisation

Phase 2

110

Angers, Bayonne, Clermont-Ferrand, Grenoble, Marseille, Montpellier, Mulhouse, Nantes

2018-10-11

Recruiting

Clinical and Biological Database in Colon Cancer and Colic Tumors

NCT03976960Cancer Colon

Institut du Cancer de Montpellier - Val d'Aurelle

Not applicable

600

Montpellier

2018-09-19

Active, closed

Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)

NCT03553836Melanoma

DrugsKeytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

976

Marseille, Dijon, Bordeaux, Toulouse, Boulogne-Billancourt, Montpellier, Rennes, Angers

2018-09-12

Active, closed

A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis

NCT03398135Ulcerative Colitis (UC)

DrugsSkyrizi·Risankizumab

AbbVie

Phase 3

1,242

Nice, Marseille, Montpellier, Vandœuvre-lès-Nancy, Pessac, Saint Priest EN Jarez, Amiens, Nantes

2018-08-28

Recruiting

A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS)

NCT02991469Juvenile Idiopathic Arthritis

DrugSarilumab

Sanofi

Phase 2

Bron, Montpellier, Paris

2018-08-09

Active, closed

Detection of the Emergence of RAS (Rat Sarcoma Viral Oncogene Homolog) Mutations in Circulating DNA (Deoxyribonucleic Acid) in Patients With mCRC (Metastatic Colorectal Cancer) During Treatment With Anti-EGFR (Epidermal Growth Factor Receptor) Therapy

NCT03908788Metastatic Colorectal Cancer

Institut du Cancer de Montpellier - Val d'Aurelle

Not applicable

130

Montpellier

2018-07-26

Active, closed

A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension

NCT03492177Pulmonary Arterial Hypertension

DrugSelexipag

Actelion

Phase 2

Montpellier, Paris, Toulouse

2018-07-23

Recruiting

Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

NCT03435796Neoplasms

Celgene

Phase 2/3

1,541

Creteil-Paris, Lille, Lyon, Marseille, Montpellier, Nantes, Paris, Pessac

2018-07-19

Active, closed

A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

NCT03519945Ulcerative Colitis

DrugMirikizumab

Eli Lilly and Company

Phase 3

1,058

Amiens, Chambray-lès-Tours, Lille, Montpellier, Neuilly-sur-Seine, Nice, Paris, Pau

2018-07-18

Active, closed

Two Chemotherapy Regimens Plus or Minus Bevacizumab

NCT03351296Pancreatic Cancer

DrugsLV5FU2·Temozolomide·Capecitabine·Bevacizumab

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2

140

Nice, Caen, Dijon, Pessac, Toulouse, Clichy, Montpellier, Chambray-lès-Tours

2018-06-26

Active, closed

First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma

NCT03625037DLBCL, High-grade B-cell Lymphoma (HGBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL), FL

DrugEpcoritamab

Genmab

Phase 1/2

666

Créteil, Montpellier, Paris, Pierre-Bénite, Rouen, Tours

2018-06-26

Recruiting

IMRT and Primary Transoral Surgery in the Treatment of Squamous Cell Carcinomas

NCT04224389Squamous Cell Carcinoma

Gustave Roussy, Cancer Campus, Grand Paris

Observational

150

Villejuif, Créteil, Lille, Lyon, Marseille, Montpellier, Nantes, Nice

2018-06-22

Active, closed

A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.

NCT03504397Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

DrugsFolinic acid·Zolbetuximab·Fluorouracil·Oxaliplatin

Astellas Pharma Global Development, Inc.

Phase 3

565

Dijon, Brest, Rennes, Besançon, Montpellier, Paris, Saint-Herblain, Nice

2018-06-21

Active, closed

Clinical Database of Colorectal Robotic Surgery

NCT04013152Crohn Disease, Polyposis, Ulcerative Colitis, Diverticulitis

Institut du Cancer de Montpellier - Val d'Aurelle

Observational

1,800

Bordeaux, Montpellier, Clermont-Ferrand, Lyon

2018-06-13

Recruiting

Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepatic Cholangiocarcinoma

NCT03364530Cholangiocarcinoma Non-resectable, Non-metastatic

DrugGemcitabine & oxaliplatin

University Hospital, Montpellier

Phase 2

Amiens, Angers, Bordeaux, Dijon, Montpellier, Paris, Villejuif

2018-06-11

Recruiting

Sentinel. Ambulatory. Oral Cavity. Oropharynx (S.A.C.O)

NCT03545256Cancer T1-N0 or T2-N0 of the Oral Cavity

University Hospital, Montpellier

Not applicable

Montpellier

2018-05-31

Recruiting

Analysis of Circulating Tumor Markers in Blood

NCT04025541Cancer, Breast Cancer, Sarcoma, Lung Cancers

DrugBlood sampling

Institut du Cancer de Montpellier - Val d'Aurelle

Not applicable

992

Montpellier

2018-05-29

Active, closed

A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis

NCT03523858Progressive Multiple Sclerosis (PMS)

DrugOcrelizumab

Hoffmann-La Roche

Phase 3

927

Bayonne, Bordeaux, Bron, Caen, Clermont-Ferrand, Lille, Marseille, Montpellier

2018-05-28

Active, closed

Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer

NCT03528694Non-muscle-invasive Bladder Cancer

DrugsBacillus Calmette-Guerin·Durvalumab

AstraZeneca

Phase 3

1,018

Amiens, Angers, Bordeaux, Lyon, Marseille, Montpellier, Strasbourg, Suresnes

2018-05-14

Recruiting

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

NCT03526835Advanced/Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer

DrugPetosemtamab

Merus B.V.

Phase 1/2

560

Bordeaux, Lyon, Marseille, Montpellier, Nice, Paris, Rouen

2018-05-02

Recruiting

Effects of Variation of Sodium Dialysate in ICU

NCT03329313Acute Kidney Injury, Renal Replacement Therapy

University Hospital, Montpellier

Phase 2

158

Montpellier

2018-04-19

Active, closed

A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

NCT03462719Leukemia, Lymphocytic, Chronic, B-Cell

DrugsChlorambucil·Ibrutinib·Obinutuzumab·Venetoclax

Janssen Research & Development, LLC

Phase 3

211

Clermont-Ferrand, Lille, Montpellier, Pessac, Reims, Toulouse, Tours, Vandœuvre-lès-Nancy

2018-04-17

Active, closed

A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease

NCT03105102Crohn's Disease

DrugsSkyrizi·Risankizumab

AbbVie

Phase 3

1,336

Nice, Montpellier, La Tronche, Vandœuvre-lès-Nancy, Pessac, Lille, St-Priest-en-Jarez, Pierre-Bénite

2018-04-09

Recruiting

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

NCT03424005Metastatic Breast Cancer

DrugsAtirmociclib·Ipatasertib·Giredestrant·Inavolisib

Hoffmann-La Roche

Phase 1/2

1,132

Lyon, Montpellier, Toulouse, Villejuif

2018-03-30

Active, closed

A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433

NCT03345823Crohn's Disease

DrugUpadacitinib

AbbVie

Phase 3

747

Nice, Pessac, Toulouse, Montpellier, La Tronche, Vandœuvre-lès-Nancy, Lille, Valenciennes

2018-03-21

Active, closed

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

NCT03330847Metastatic Triple Negative Breast Cancer

DrugCeralasertib

AstraZeneca

Phase 2

273

Angers, Besançon, Bordeaux, Caen, Lille, Lyon, Marseille, Montpellier

2018-03-07

Recruiting

FARD (RaDiCo Cohort) (RaDiCo-FARD)

NCT05954416Inherited Epidermolysis Bullosa, Ichthyosis, Ectodermal Dysplasia, Incontinentia Pigmenti

Institut National de la Santé Et de la Recherche Médicale, France

Observational

900

Bobigny, Bordeaux, Créteil, Dijon, Limoges, Marseille, Montpellier, Nice

2018-03-07

Recruiting

Creation of a Clinical Database on Primary Nervous System Tumors

NCT04516720Nervous System Tumor

Institut du Cancer de Montpellier - Val d'Aurelle

Observational

1,700

Montpellier

2018-01-01

Recruiting

New Biomarkers in Pancreatic Cancer Using EXPEL Concept

NCT03791073Oncology

University Hospital, Montpellier

Observational

200

Montpellier

2018-01-01

Recruiting

The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR

NCT03142152Functional Mitral Regurgitation, Heart Failure, Mitral Valve Insufficiency, Heart Diseases

Cardiac Dimensions, Inc.

Not applicable

300

Clermont-Ferrand, Lille, Lyon, Montpellier, Paris

2018-01-01

Active, closed

Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC

NCT03395197mCRPC

Pfizer

Phase 3

1,054

Le Mans, Bayonne, Bordeaux, La Roche-sur-Yon, Lyon, Montpellier, Paris, Strasbourg

2017-12-18

Active, closed

LEAn Body Mass Normalization of OXaliplatin Based Chemotherapy

NCT03255434Stage III Colon Cancer

DrugOxaliplatin

Institut du Cancer de Montpellier - Val d'Aurelle

Phase 2

160

Marseille, Montpellier, Vandœuvre-lès-Nancy, Perpignan, Caen, Paris, Rennes, Strasbourg

2017-11-01

Active, closed

Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults

NCT03299049HIV Infections

DrugsRilpivirine·Cabotegravir

ViiV Healthcare

Phase 3

1,049

Montpellier, Paris, Saint-Denis, Toulouse, Tourcoing

2017-10-27

Active, closed

Cognitive Behavioural Group Therapy Versus Individual Supportive Therapy for the Prevention of Repeat Suicide Attempts

NCT02664701Suicidal Ideation, Suicide, Attempt

Centre Hospitalier Universitaire de Nīmes

Not applicable

240

Clermont-Ferrand, Lyon, Montpellier, Nîmes, Paris, Poitiers, Saint-Cyr-sur-Loire, Strasbourg

2017-10-17

Active, closed

Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

NCT03298451Hepatocellular Carcinoma

DrugsSorafenib·Tremelimumab·Durvalumab

AstraZeneca

Phase 3

1,324

Clichy, Lille, Marseille, Montpellier, Nancy, Nantes, Nice, Pessac

2017-10-11

Recruiting

Registry for Patients With X-Linked Hypophosphatemia

NCT03193476X-Linked Hypophosphatemia

Kyowa Kirin Pharmaceutical Development Ltd

Observational

1,489

Bordeaux, Bron, Lille, Montpellier, Nantes, Paris, Toulouse

2017-09-12

Recruiting

Development of Clinical and Biological Database

NCT03449264Digestive Cancer, Gynecologic Cancer, Breast Cancer, Sarcoma

DrugBiological collection

Institut du Cancer de Montpellier - Val d'Aurelle

Not applicable

4,000

Montpellier

2017-07-27

Active, closed

Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer

NCT03155997Breast Cancer

DrugAbemaciclib

Eli Lilly and Company

Phase 3

5,637

Lyon, Brest, La Chaussée-Saint-Victor, Dijon, Plérin, Besançon, Rennes, Montpellier

2017-07-12

Recruiting

Development of a Cinical and Biological Database in Ovarian, Fallopian Tube and Peritoneal Cancers

NCT03976999Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Peritoneal Neoplasms

Institut du Cancer de Montpellier - Val d'Aurelle

Not applicable

300

Montpellier

2017-07-05

Active, closed

A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)

NCT03157128Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor

DrugSelpercatinib

Eli Lilly and Company

Phase 1/2

857

Bordeaux, Lyon, Marseille, Montpellier, Villejuif, Paris

2017-05-02

Recruiting

Analysis of Sympathetic Activity in Willis-Ekbom Disease

NCT02929732Willis-Ekbom Disease, Restless Legs Syndrome

University Hospital, Montpellier

Not applicable

Montpellier

2017-03-21

Active, closed

A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors

NCT02988960Advanced Solid Tumors Cancer

DrugsABBV-927·Budigalimab

AbbVie

Phase 1

163

Bordeaux, Montpellier, Lyon, Villejuif

2017-02-22

Active, closed

A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma

NCT03075696Non-Hodgkin's Lymphoma

DrugsGlofitamab·Tocilizumab·Obinutuzumab

Hoffmann-La Roche

Phase 1/2

940

Créteil, Lille, Montpellier, Pierre-Bénite, Rennes

2017-02-21

Active, closed

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

NCT02970318Chronic Lymphocytic Leukemia

DrugsIdelalisib·Acalabrutinib·Bendamustine·Rituximab

Acerta Pharma BV

Phase 3

310

Bordeaux, Brest, Montpellier, Nantes, Paris, Perpignan, Provence Alpes Cote D'Azur, Rennes

2017-02-02

Active, closed

Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients

NCT03049189Neuroendocrine Tumors

Drugs177Lu-DOTATOC·Everolimus

ITM Solucin GmbH

Phase 3

324

Bron, Clermont-Ferrand, Clichy, Montpellier, Nantes, Toulouse

2017-02-02

Active, closed

A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)

NCT03006068Ulcerative Colitis (UC)

DrugUpadacitinib

AbbVie

Phase 3

950

Nice, Montpellier, Lille, Pierre-Bénite, La Roche-sur-Yon, Saint-Etienne

2017-01-31

Recruiting

Oedema Study : Chroedem

NCT02914808Lower Limb Chronic Oedema

University Hospital, Montpellier

Observational

Grenoble, Montpellier, Nîmes

2017-01-03

Active, closed

A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

NCT02960022Prostate Cancer

DrugsLeuprolide Acetate·Xtandi·Abiraterone acetate·Enzalutamide

Astellas Pharma Global Development, Inc.

Phase 2

900

Bordeaux, La Roche-sur-Yon, Lille, Lyon, Montpellier, Nîmes, Paris, Saint-Herblain

2016-12-22

Active, closed

An Observational Prospective Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative Colitis

NCT02808780Ulcerative Colitis

Janssen Biotech, Inc.

Observational

535

Clermont-Ferrand, Clichy, Créteil, Grenoble, Montpellier, Nice, Pierre-Bénite, Saint-Priest-en-Jarez

2016-12-16

Active, closed

A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer

NCT02779751Non Small Cell Lung Cancer, Breast Cancer

DrugsAnastrozole·Abemaciclib·Pembrolizumab

Eli Lilly and Company

Phase 1

100

Lille, Montpellier, Toulouse

2016-11-14

Recruiting

Establishment of a Prospective Clinical-biological Database

NCT04458792Sarcoma

Institut du Cancer de Montpellier - Val d'Aurelle

Not applicable

450

Montpellier

2016-11

Active, closed

Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults

NCT02951052Infection, Human Immunodeficiency Virus, HIV Infections

Drugs2 NRTIs·Cabotegravir (CAB)·Rilpivirine (RPV)·Rilpivirine

ViiV Healthcare

Phase 3

618

Montpellier, Paris, Saint-Denis, Toulouse, Tourcoing

2016-10-28

Active, closed

Mouth Opening, Prevention, Education, Nutrition (OPEN)

NCT03979924Trismus, Head and Neck Cancer

Institut du Cancer de Montpellier - Val d'Aurelle

Not applicable

175

Nîmes, Amiens, Avignon, Clermont-Ferrand, Montpellier, Saint-Pierre

2016-10-20

Active, closed

Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma

NCT02811861Renal Cell Carcinoma

DrugsSunitinib·Everolimus·Lenvatinib·Pembrolizumab

Eisai Inc.

Phase 3

1,069

Angers, Dijon, Le Mans, Lyon, Montpellier, Paris, Saint-Herblain, Strasbourg

2016-10-13

Recruiting

A Clinicobiological Database in Metastatic Digestive Cancers

NCT03978078Digestive System Neoplasm

Institut du Cancer de Montpellier - Val d'Aurelle

Not applicable

200

Montpellier

2016-09-12

Active, closed

Evaluation of Late Toxicity Following Intensity-Modulated Radiotherapy and Two Image-Guided Strategies With Corresponding Treatment Margins.

NCT03254420Prostate Cancer

Institut du Cancer de Montpellier - Val d'Aurelle

Not applicable

Montpellier

2016-08-30

Active, closed

Tools for Therapeutic Evaluation in Charcot-Marie-Tooth Disease Type 1A: Outcome Measures and Biomarkers

NCT02596191Charcot-Marie-Tooth Disease Type 1A

Assistance Publique Hopitaux De Marseille

Not applicable

Marseille, Montpellier

2016-06-06

Active, closed

eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients

NCT02767804Non-small Cell Lung Cancer

DrugsEnsartinib·Crizotinib

Xcovery Holdings, Inc.

Phase 3

290

Lille, Montpellier, Rennes, Vellefaux

2016-06

Active, closed

A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer

NCT02711553Biliary Tract Cancer, Metastatic Cancer, Advanced Cancer

DrugsRamucirumab·Gemcitabine·Cisplatin

Eli Lilly and Company

Phase 2

309

Lyon, Bordeaux, Besançon, Lille, Montpellier, Nice, Villejuif

2016-05-19

Recruiting

Correction of Nonsense Mutations in Cystic Fibrosis

NCT03670472Cystic Fibrosis

University Hospital, Lille

Observational

Amiens, Bron, Lille, Marseille, Montpellier, Paris, Strasbourg

2016-02-03

Recruiting

Collection of Human Metabolic Tissues

NCT02861781Obesity, Insulin Resistance, Diabetes Mellitus, Type 2

University Hospital, Montpellier

Observational

270

Montpellier

2016-02-02

Recruiting

Incidence and Risk Factor of Drug Related Problem Detected in Inpatient

NCT03476733Drug Related Problem

University Hospital, Montpellier

Observational

20,000

Montpellier

2016-01-01

Active, closed

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate

NCT02629159Rheumatoid Arthritis

DrugsHumira·Adalimumab·Upadacitinib

AbbVie

Phase 3

1,629

Toulouse, Lille, Montpellier, Bordeaux, Caen, Clermont-Ferrand, Marseille, Paris

2015-12-01

Active, closed

A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC

NCT02489318Prostate Cancer

DrugApalutamide

Aragon Pharmaceuticals, Inc.

Phase 3

1,052

Clermont-Ferrand, Montpellier, Nancy, Paris, Pierre-Bénite, Strasbourg, Suresnes

2015-11-27

Active, closed

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

NCT02568267Breast Cancer, Cholangiocarcinoma, Colorectal Cancer, Head and Neck Neoplasms

DrugEntrectinib

Hoffmann-La Roche

Phase 2

534

Angers, Bordeaux, Lyon, Marseille, Montpellier, Paris, Toulouse, Villejuif

2015-11-19

Active, closed

Avenir® Cemented Hip Stem - PMCF

NCT03396224Primary Osteoarthritis, Post-Traumatic Osteoarthritis of Hip, Femoral Neck Fractures, Femoral Head Necrosis

Zimmer Biomet

Observational

100

Clermont-Ferrand, Montpellier

2015-11-18

Active, closed

Phase III Radium 223 mCRPC-PEACE III

NCT02194842Prostate Cancer

DrugsRa223·Enzalutamide

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3

446

Angers, Caen, Créteil, Lyon, Montpellier, Saint-Herblain, Strasbourg, Villejuif

2015-10

Recruiting

Measure of the Potential Evoked by Electric Stimulation

NCT02509442Low Grade Glioma of Brain

University Hospital, Montpellier

Not applicable

Montpellier

2015-07-22

Recruiting

An International Clinical Program for the Diagnosis and Treatment of Children With Ependymoma

NCT02265770Childhood Ependymoma

DrugsValproate·CDDP·Vincristine·Methotrexate

Centre Leon Berard

Phase 2/3

536

Strasbourg, Marseille, Dijon, Besançon, Brest, Bordeaux, Toulouse, Montpellier

2015-06-02

Active, closed

A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)

NCT02411448Metastatic Non-Small Cell Lung Cancer

DrugsGefitinib·Erlotinib·Ramucirumab·Osimertinib

Eli Lilly and Company

Phase 3

545

Montpellier, La Tronche, Lille, Poitiers, Paris

2015-05-06

Active, closed

Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

NCT02319837Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate

DrugsLupron·Eligard·Leuprorelin·Xtandi

Pfizer

Phase 3

1,068

Angers, Brest, La Roche-sur-Yon, Lille, Montpellier, Nantes, Paris, Saint-Grégoire

2014-12-17

Active, closed

An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT02257736Prostatic Neoplasms

DrugsZytiga·Apalutamide·Abiraterone acetate·Prednisone

Aragon Pharmaceuticals, Inc.

Phase 3

982

Angers, Caen, Dijon, Le Mans, Lyon, Montpellier, Paris, Saint-Herblain

2014-11-26

Active, closed

A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer

NCT02246621Breast Cancer

DrugsAnastrozole·Abemaciclib·Letrozole

Eli Lilly and Company

Phase 3

493

Bordeaux, Lyon, Brest, Dijon, Saint-Brieuc, Montpellier, Saint-Herblain, Nancy

2014-11-06

Active, closed

Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

NCT02227251Diffuse Large B-cell Lymphoma

DrugSelinexor

Karyopharm Therapeutics Inc

Phase 2

244

Pierre-Bénite, Créteil, Dijon, La Rochelle, Lille, Marseille, Montpellier, Paris

2014-11

Recruiting

Development of a Clinical and Biological Database in Rectum Cancer

NCT04006951Rectal Neoplasms

Institut du Cancer de Montpellier - Val d'Aurelle

Not applicable

300

Montpellier

2014-10-08

Active, closed

TARGIT-C(Consolidation) Prospective Phase IV Study of IORT in Patients With Small Breast Cancer

NCT02290782Breast Cancer

Universitätsmedizin Mannheim

Not applicable

387

Montpellier, Toulouse

2014-10

Recruiting

Prospective Evaluation of the Efficacy of Sirolimus (Rapamune®) in the Treatment of Severe Arteriovenous Malformations

NCT02042326Arteriovenous Malformations

DrugsRapamycin·Sirolimus

Centre Hospitalier Universitaire, Amiens

Phase 2

Amiens, Bordeaux, Dijon, Lille, Lyon, Marseille, Montpellier, Nancy

2014-09-12

Cite this view

Priya Life Science (2026). Clinical trial register: studies with a French investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 27 October 2026. https://priyalifescience.com/clinical-trials-france/city/montpellier?page=2

Query this register directly

GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in France and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,697 studies in total at the last sync on 26 Oct 2026, 03:20 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,023 of those studies with a site in Montpellier.

How many clinical trials are recruiting in Montpellier?

577 of the 1,023 studies on this page are recruiting new participants as of the 26 Oct 2026, 03:20 UTC sync. A further 90 have not yet opened recruitment, 346 are active but closed to new participants, and 10 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.